![[Valid RSS]](images/valid-rss-rogers.png "Valid RSS")
This is a valid RSS feed.
This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.
line 39, column 0: (7 occurrences) [help]
<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" ...
line 40, column 0: (35 occurrences) [help]
<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img wi ...
line 144, column 0: (15 occurrences) [help]
<p><b>About the Jaguar Corridor Initiative<br /></br></b>Panthera’s Ja ...
line 161, column 0: (6 occurrences) [help]
<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" ...
<div dir="ltr" id="prni_dvprnejpg970bleft" style="width: 100%; text-align: l ...
<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" > <channel> <title>Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight | The News This Week</title> <atom:link href="https://thenewsthisweek.co.uk/feed/" rel="self" type="application/rss+xml" /> <link>https://thenewsthisweek.co.uk</link> <description></description> <lastBuildDate>Wed, 30 Apr 2025 21:31:00 +0000</lastBuildDate> <language>en-GB</language> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <generator>https://wordpress.org/?v=6.8.1</generator> <image> <url>https://thenewsthisweek.co.uk/wp-content/uploads/2023/07/cropped-TNTW-logo-2-32x32.png</url> <title>Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight | The News This Week</title> <link>https://thenewsthisweek.co.uk</link> <width>32</width> <height>32</height></image> <item> <title>Roche’s Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight</title> <link>https://thenewsthisweek.co.uk/roches-susvimo-fda-approval-marks-new-era-in-diabetic-macular-edema-treatment-market-delveinsight-19166/</link> <dc:creator><![CDATA[PR Newswire]]></dc:creator> <pubDate>Wed, 30 Apr 2025 21:31:00 +0000</pubDate> <category><![CDATA[Brand Post]]></category> <guid isPermaLink="false">https://thenewsthisweek.co.uk/roches-susvimo-fda-approval-marks-new-era-in-diabetic-macular-edema-treatment-market-delveinsight-19166/</guid> <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="65" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/05/roches-susvimo-fda-approval-marks-new-era-in-diabetic-macular-edema-treatment-market-delveinsight.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" /></div>Seven months after the FDA approved the reintroduction of Roche’s eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary cause of blindness related to diabetes. This marks the second approved indication for Susvimo, which was initially cleared in October 2021 as an alternative to […]]]></description> <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="65" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/05/roches-susvimo-fda-approval-marks-new-era-in-diabetic-macular-edema-treatment-market-delveinsight.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" /></div><p><b><i>Seven months after the FDA approved the reintroduction of Roche’s eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary cause of blindness related to diabetes. This marks the second approved indication for Susvimo, which was initially cleared in <span class="xn-chron">October 2021</span> as an alternative to frequent eye injections for wet age-related macular degeneration.</i></b></p><p><span class="legendSpanClass"><span class="xn-location">LAS VEGAS</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 30, 2025</span></span> /PRNewswire/ — Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a leading cause of irreversible vision loss in working-age adults globally. Diabetic retinopathy occurs due to long-term damage to the retina’s small blood vessels, leading to fluid leakage and swelling—especially in the macula. As per DelveInsight’s analysis, there were about <b>1.9 million</b> prevalent cases of DME across the 7MM in 2023, with numbers expected to grow at a notable CAGR during the forecast period.</p><div dir="ltr" id="prni_dvprnejpgdf1fleft" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="DelveInsight Logo" id="prnejpgdf1fleft" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" style="width: 400px; height: 181px;" title="DelveInsight Logo"></img></div><p>The primary treatment for DME includes intravitreal injections, where the eye is numbed with drops before injecting medication directly into the vitreous humor. Common anti-VEGF drugs used include <b>AVASTIN, EYLEA, and LUCENTIS</b>. Additionally, corticosteroids are beneficial in cases of DME linked to inflammatory eye conditions and can be delivered via eye drops, oral tablets, or periocular injections to help reduce inflammation. The US FDA approved sustained-release corticosteroid implants for more serious or longer-lasting conditions, are <b>OZURDEX, RETISERT, and ILUVIEN.</b></p><p>Learn more about the diabetic macular edema treatment @ <b><a href="http://delveinsight.com/sample-request/diabetic-macular-edema-dme-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr" rel="nofollow" target="_blank">New Treatment for Diabetic Macular Edema</a></b></p><p><b>EYLEA (Regeneron Pharmaceuticals)</b> – Aflibercept is a recombinant fusion protein composed of the VEGF-binding regions derived from the extracellular domains of human VEGF receptors 1 and 2, linked to the Fc segment of human IgG1. It functions as a VEGF trap by binding to circulating vascular endothelial growth factors (VEGFs), thereby neutralizing VEGF-A, VEGF-B, and placental growth factor (PGF). This action inhibits the formation of new blood vessels in the tumor’s choriocapillaris. In <span class="xn-chron">July 2014</span>, the U.S. FDA approved EYLEA (aflibercept) Injection for treating diabetic macular edema (DME).</p><p><b>Ranibizumab (Genentech)</b> – Marketed as LUCENTIS, ranibizumab is a monoclonal antibody fragment (Fab) derived from the same original mouse antibody as bevacizumab. It is an anti-angiogenic therapy used to treat the “wet” form of age-related macular degeneration (AMD), a leading cause of vision loss in older adults. Ranibizumab has shown comparable effectiveness to bevacizumab. Developed by Genentech, it is marketed in the U.S. by Genentech and internationally by Novartis. The FDA approved ranibizumab for the treatment of DME in 2012.</p><p>In <span class="xn-chron">February 2025</span>, Roche announced that the FDA had approved Susvimo (ranibizumab injection) 100 mg/mL for treating diabetic macular edema (DME), a major cause of vision loss in adults with diabetes. This approval is based on positive one-year data from the phase III Pagoda trial, which demonstrated that Susvimo offered sustained improvements in vision for individuals with DME, with a safety profile consistent with what is already known for the drug. In the study, patients receiving Susvimo refills every six months experienced vision gains comparable to those receiving monthly intravitreal injections of 0.5 mg ranibizumab (9.6 letters versus 9.4 letters on an eye chart, equivalent to about two lines of vision improvement).</p><p>Susvimo delivers a specially formulated version of ranibizumab continuously through the Port Delivery Platform, offering a less frequent dosing alternative compared to other treatments that may require monthly eye injections. The FDA initially approved Susvimo in 2021 for the treatment of neovascular age-related macular degeneration (nAMD). Regulatory reviews in other countries are currently underway.</p><p>Learn more about the FDA-approved DME drugs @ <b><a href="http://delveinsight.com/sample-request/diabetic-macular-edema-dme-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr" rel="nofollow" target="_blank">Drugs for Diabetic Macular Edema Treatment</a></b></p><p>Key players, such as <b>Oculis, Rezolute, AsclepiX Therapeutics</b>, and others, are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of diabetic macular edema. The DME market has a promising outlook with the emerging therapies. Some of the drugs in the pipeline are <b>OCS-01, RZ402, AXT107</b>, and others. </p><p>DME leads to significant vision loss in diabetics, affecting up to 7.9% of type 1 and 12.8% of type 2 diabetes patients. <b>AbbVie</b>, in collaboration with <b>REGENEXBIO</b>, is developing the gene therapy <b>ABBV-RGX-314</b>. This therapy targets wet age-related macular degeneration, diabetic retinopathy (DR), and other chronic retinal diseases, potentially offering a breakthrough in treating these conditions.</p><p>Discover which therapies are expected to grab major DME market share @ <b><a href="http://delveinsight.com/sample-request/diabetic-macular-edema-dme-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr" rel="nofollow" target="_blank">Diabetic Macular Edema Market Report</a></b></p><p><b>OCS-01</b> is a high-concentration dexamethasone eye drop developed for diabetic macular edema (DME), utilizing the proprietary Optireach solubilizing platform. This technology enhances drug solubility, allows for higher concentrations, prolongs ocular retention, and improves bioavailability in eye tissues, including the retina. </p><p>Recently, in <span class="xn-chron">April 2025</span>, Oculis announced the completion of patient enrollment for its Phase 3 <b>DIAMOND-1 and DIAMOND-2 clinical trials</b> evaluating OCS-01 eye drops for diabetic macular edema (DME). These pivotal registration studies aim to support global regulatory filings, including a New Drug Application (NDA) submission and potential approval by the U.S. FDA. Over 800 patients were enrolled across 119 sites in the U.S. and other countries.</p><p>The swift completion of enrollment in the DIAMOND program—comprising two double-masked, randomized, multi-center Phase 3 trials—is a significant milestone. These studies are assessing the efficacy and safety of OCS-01 over a 52-week treatment period in patients with DME. Topline results are anticipated in Q2 2026, followed by an NDA submission.</p><p>If approved, OCS-01 would be the first topical eye drop treatment for DME, offering a novel therapeutic option for early intervention and for patients who do not adequately respond to anti-VEGF therapies.</p><p><b>RZ402</b> is an oral small-molecule drug that selectively inhibits plasma kallikrein (PK) for the long-term treatment of DME. By blocking kallikrein activation, RZ402 aims to prevent bradykinin-driven vascular leakage and inflammation. Phase II results revealed a significant reduction in central subfield thickness (CST) across all dosing levels, with improvements of up to ~50 microns compared to placebo. The treatment was well tolerated and showed a favorable safety profile.</p><p><b>AXT107</b> targets two validated mechanisms for treating retinal vascular diseases: it inhibits the pro-angiogenic receptor VEGFR2 and activates the vessel-stabilizing Tie2 receptor. These effects are mediated through its interaction with integrins αvβ3 and α5β1. AXT107 is formulated as a microparticulate suspension designed for intraocular injection and is currently undergoing Phase I/II clinical trials, according to the company’s development pipeline.</p><p>Discover more about drugs for DME in development @ <b><a href="http://delveinsight.com/sample-request/diabetic-macular-edema-dme-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr" rel="nofollow" target="_blank">Diabetic Macular Edema Clinical Trials</a></b></p><p>The anticipated launch of these emerging therapies for DME are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the DME market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.</p><p>DelveInsight estimates that the market size for DME is expected to grow from <b><span class="xn-money">USD 3 billion</span></b> in 2023, with a significant CAGR by 2034. Owing to the higher patient pool and higher diabetic macular edema treatment cost, according to the estimates, <span class="xn-location">the United States</span> had the highest market size in DME, i.e., <b>~60%</b> of the total market size of DME in the 7MM, in 2023, followed by <span class="xn-location">Germany</span> and <span class="xn-location">Japan</span>.</p><p>DelveInsight’s analysis forecasts market growth due to the introduction of emerging therapies, expecting a rise in market size during the study period (2020–2034). The anticipated increase in market size is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition, which together foster higher demand for innovative and effective therapies.</p><p>DelveInsight’s latest published market report, titled as <b><a href="https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr" rel="nofollow" target="_blank">Diabetic Macular Edema Market Insight, Epidemiology, and Market Forecast – 2034</a></b><b>, </b>will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the DME country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market’s underlying potential. The DME market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:</p><ul type="disc"><li>Total Prevalent Cases of DME</li><li>Total Diagnosed Prevalent Cases of DME</li><li>Gender-specific Diagnosed Prevalent Cases of DME</li><li>Age-Specific Diagnosed Prevalent Cases of DME</li><li>Subgroup-specific Diagnosed Prevalent Cases of DME</li></ul><p>The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM DME market. Highlights include:</p><ul type="disc"><li>10-year Forecast</li><li>7MM Analysis</li><li>Epidemiology-based Market Forecasting</li><li>Historical and Forecasted Market Analysis upto 2034</li><li>Emerging Drug Market Uptake</li><li>Peak Sales Analysis</li><li>Key Cross Competition Analysis</li><li>Industry Expert’s Opinion</li><li>Access and Reimbursement</li></ul><p>Download this DME market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs’ opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the DME market. Also, stay abreast of the mitigating factors to improve your market position in the DME therapeutic space.</p><p><b>Related Reports</b></p><p><b><a href="https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-epidemiology-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr" rel="nofollow" target="_blank">Diabetic Macular Edema Epidemiology Forecast</a></b></p><p><b>Diabetic Macular Edema Epidemiology Forecast – 2034</b> report delivers an in-depth understanding of the disease, historical and forecasted diabetic macular edema epidemiology in the 7MM, i.e., <span class="xn-location">the United States</span>, EU5 (<span class="xn-location">Germany</span>, <span class="xn-location">Spain</span>, <span class="xn-location">Italy</span>, <span class="xn-location">France</span>, and the <span class="xn-location">United Kingdom</span>), and <span class="xn-location">Japan</span>.</p><p><b><a href="https://www.delveinsight.com/report-store/diabetic-macular-edema-pipeline-insight?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr" rel="nofollow" target="_blank">Diabetic Macular Edema Pipeline</a></b></p><p><b>Diabetic Macular Edema Pipeline Insight </b><b>– 2025</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic macular edema companies, including <b>Mylan Pharmaceuticals, Kodiak Sciences, Celltrion, Exonate, Opthea, AsclepiX Therapeutics, Allgenesis Biotherapeutics, Ascentage Pharma, Rezolute, Ocuphire Pharma, Oxurion, MingSight Pharmaceuticals, Adverum Biotechnologies, </b>among others.</p><p><b><a href="https://www.delveinsight.com/report-store/diabetic-retinopathy-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr" rel="nofollow" target="_blank">Diabetic Retinopathy Market</a></b></p><p><b>Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast – 2034 </b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic retinopathy companies, including <b>Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis,</b> among others.</p><p><b><a href="https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr" rel="nofollow" target="_blank">Diabetic Retinopathy Pipeline</a></b></p><p><b>Diabetic Retinopathy Pipeline Insight </b><b>– 2025</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic retinopathy companies, including <b>Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, Palatin Technologies, Valo Health, EyePoint Pharmaceuticals, Kubota Vision, MingSight Pharmaceuticals, Oxurion, Aerie Pharmaceuticals, AsclepiX Therapeutics, Ocugen, Ashvattha Therapeutics, Stealth BioTherapeutics, </b>among others.</p><p><b>About DelveInsight</b></p><p>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve<b>.</b></p><p><b>Contact Us<br /></br></b><span class="xn-person">Shruti Thakur</span><br /></br><a href="mailto:info@delveinsight.com" rel="nofollow" target="_blank">info@delveinsight.com</a> <br /></br>+14699457679</p><p>Logo: <a href="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg</a></p><p> </p><p id="PURL"><img decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN76518&sd=2025-04-30" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/roches-susvimo-fda-approval-marks-new-era-in-diabetic-macular-edema-treatment-market--delveinsight-302442182.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/roches-susvimo-fda-approval-marks-new-era-in-diabetic-macular-edema-treatment-market–delveinsight-302442182.html</a></p><p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN76518&Transmission_Id=202504301731PR_NEWS_EURO_ND__EN76518&DateId=20250430" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>]]></content:encoded> </item> <item> <title>Everland in partnership with BNP Paribas announces $50 million capital markets initiative to launch first Indigenous-led Amazon forest conservation projects under Equitable Earth Standard</title> <link>https://thenewsthisweek.co.uk/everland-in-partnership-with-bnp-paribas-announces-50-million-capital-markets-initiative-to-launch-first-indigenous-led-amazon-forest-conservation-projects-under-equitable-earth-standard-19168/</link> <dc:creator><![CDATA[PR Newswire]]></dc:creator> <pubDate>Wed, 30 Apr 2025 21:00:00 +0000</pubDate> <category><![CDATA[Brand Post]]></category> <guid isPermaLink="false">https://thenewsthisweek.co.uk/everland-in-partnership-with-bnp-paribas-announces-50-million-capital-markets-initiative-to-launch-first-indigenous-led-amazon-forest-conservation-projects-under-equitable-earth-standard-19168/</guid> <description><![CDATA[Designed to mobilize billions of dollars for forest communities and conservation, this initiative aims to drive action on global goals for climate, nature and sustainable development NEW YORK, April 30, 2025 /PRNewswire/ — Everland is convening, with the support of BNP Paribas, a groundbreaking outcome bond partnership to finance large-scale, Indigenous and traditional community-led forest conservation […]]]></description> <content:encoded><![CDATA[<p class="prntac"><b>Designed to mobilize billions of dollars for forest communities and conservation, this initiative aims to drive action on global goals for climate, nature and sustainable development</b></p><p><span class="legendSpanClass"><span class="xn-location">NEW YORK</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 30, 2025</span></span> /PRNewswire/ — Everland is convening, with the support of BNP Paribas, a groundbreaking outcome bond partnership to finance large-scale, Indigenous and traditional community-led forest conservation projects. The initiative is also supported by world-leading international advocacy organization Global Citizen, as part of its ongoing partnership with the new forest conservation standard Equitable Earth, and was unveiled today at the Global Citizen NOW summit in <span class="xn-location">New York City</span>.</p><p>The bond initiative aims to provide <span class="xn-money">$50 million</span> in direct project financing to launch the first 20 community-led REDD+ forest conservation projects in the Amazon, certified under the Equitable Earth Standard. An early focus will be on funding projects located within priority landscapes established by Panthera that form the Jaguar Corridor— a mosaic of landscapes that connect and protect jaguar populations, ensuring the species’ gene flow and long-term survival. These corridors are not only vital for jaguars, but are also home to many Indigenous and traditional communities whose stewardship is essential to protecting these ecosystems.</p><p>The finance the bond initiative intends to deliver will be used to implement conservation activities that, if successful, will generate high-integrity carbon credits over the 40-year lifespan of the projects. The sale of these carbon credits is projected to generate over <span class="xn-money">$1 billion</span> in the first 10 years, ensuring the projects’ financial sustainability and delivering lasting impact for communities, biodiversity, and climate mitigation.</p><p>Crucially, the Equitable Earth Standard requires that each project agrees a fair and equitable revenue sharing plan with Indigenous and traditional communities – so communities can invest in their own development priorities.</p><p><b>Chief Uraan Anderson Suruí, Traditional Leader of the Paiter Suruí People, said:<br /></br></b>“For generations, our communities have protected the forests because we understand that our survival — and the survival of all life — depends on them. Yet too often, decisions about climate finance have been made without us, and resources have failed to reach the ground where they are needed most. With the Equitable Earth Standard and this new initiative led by Everland and BNP Paribas, a door is opening — creating a direct path for Indigenous and traditional peoples to access the financing we need to protect our territories, strengthen our cultures, and secure our future. This is not just an investment in carbon credits; it is an investment in our way of life, in the forests that sustain humanity, and in building a more just and sustainable world for all.”</p><p><b>Constance Chalchat, Global Chief Sustainability Officer, BNP Paribas Corporate & Institutional Banking said: <br /></br></b>“Conservation is about safeguarding the natural resources that underpin countries’ long-term prosperity. From forests and water systems to working lands, we help finance efforts to responsibly manage and restore nature so that ecosystems continue delivering services to communities and economies. Indigenous Peoples have safeguarded these vital ecosystems for generations, and Indigenous knowledge, combined with sustainable financial mechanisms, is essential to driving long-term investments that deliver measurable and lasting climate, biodiversity and community outcomes. This initiative exemplifies how aligning private sector investment with Indigenous expertise can secure the long-term value of forests for people, economies, and our planet.”</p><p><b><span class="xn-person">Gerald Prolman</span>, Executive Chairman, Everland said:<br /></br></b>“Early-stage funding remains one of the biggest barriers to advancing REDD+ projects. Far too many high-impact initiatives stall before they start—not because of a lack of commitment or potential, but because communities lack access to upfront capital. This initiative is a breakthrough. It unlocks financing to launch 20 transformative, Indigenous-led forest conservation projects that can deliver measurable climate, biodiversity, and social outcomes. By combining private capital with Indigenous leadership, we’re not just enabling the market to access high-integrity carbon credits—we’re investing in the people and places that provide critical ecosystem services essential to the survival of our planet.”</p><p><b>Frédéric Launay, President & CEO of Panthera, said:<br /></br></b>“In supporting and, rightly, placing the ownership of Amazon forest conservation in the hands of the world’s ultimate guardians of nature – Indigenous and traditional communities – this bond initiative brings us one step closer to realizing the vision of the Jaguar Corridor, of which my predecessor, CEO and Panthera Co-Founder, Dr. <span class="xn-person">Alan Rabinowitz</span>, dreamt. Serving up a community-centered conservation model that would benefit all to replicate, the initiative will strengthen the protection of <span class="xn-location">Latin America’s</span> biodiverse-rich forests and the interconnected human and wild life within them, while appreciating the intrinsic and superior role of Indigenous and traditional peoples in directly managing preservation of our planet. The relationships between the Indigenous and traditional communities of the Amazon and jaguars are sacred and inestimable, and if honored appropriately, will provide extraordinary momentum for the global community’s climate actions and safeguarding of critical habitats and biodiversity for generations to come.”</p><p><b><span class="xn-person">Michael Sheldrick</span>, Co-Founder and Chief Policy, Impact and Government Relations Officer, Global Citizen said: </b>“As Global Citizen continues to advocate for purposeful action to protect the Amazon—the world’s most vital carbon sink, we’re eager to support Everland and BNP Paribas’ innovative bond initiative to fund conservation projects in the region. Deforestation may begin as a local crisis but the ripple effects threaten us all. The effort to protect the Amazon, led by Indigenous communities, will protect the earth’s most critical life source for generations to come.”</p><p><b><span class="xn-person">Beto Borges</span>, Director, Communities Territorial Governance Initiative, Forest Trends and Chair, Indigenous Peoples & Local Communities Guidance Council, Equitable Earth Coalition said:<br /></br></b>“This initiative has the potential to deliver what many Indigenous communities have long called for—equitable finance that acknowledges and values their essential role in protecting some of the world’s most critical remaining forest ecosystems. Directing funding to projects aiming for certification under the Equitable Earth Standard is a significant step toward aligning private capital with Indigenous-led solutions.”</p><p><u>The Outcome Bond Partnership</u></p><p>BNP Paribas will structure the financing mechanism and is especially drawn to Everland’s commitment to community-led projects that prioritize both impacts for communities and for biodiversity. This matches the Bank’s core values of sustainability and responsible stewardship and is a key factor in their support for this initiative.</p><p>Everland will play a central role in bringing the bond initiative to life by ensuring that projects are well-prepared, high-impact, and positioned for long-term success. This includes identifying and vetting projects, conducting on-the-ground due diligence, and overseeing the development process to ensure projects meet the requirements for the project finance milestone payments. Everland will also lead the marketing of carbon credits for the portfolio of forest conservation projects, representing their interests in the international market.</p><p><u>The Projects</u></p><p>Projects financed under the bond initiative must meet high-integrity conservation and community development criteria under the Equitable Earth Standard. As a payment-for-performance model, Equitable Earth ensures that Indigenous and traditional communities receive direct investment based on the successful conservation of critical ecosystems.</p><p>A key focus of this initiative will be projects in at-risk landscapes within the Jaguar Corridor, in the core jaguar population within the Amazon, which is the world’s largest connected habitat for jaguars. Investments in the conservation of this core jaguar population will help protect millions of hectares of forest that are vital to the survival of the jaguar, and the countless other species that inhabit these ecosystems. These forests are also the ancestral homelands of Indigenous and traditional communities, who have long served as their guardians. This initiative will channel resources directly to these communities, providing investment to confront growing threats to their forests, their rights, and to sustain their way of life.</p><p><u>High-integrity carbon credits</u></p><p>The climate impact of the projects will be measured by their ability to reduce ongoing deforestation that would otherwise continue. This generates verified carbon credits, each representing one ton of CO₂ prevented from entering the atmosphere. Emissions reductions will be third-party verified and tied to measurable avoided deforestation, thereby providing companies with a tangible way to meet their climate goals while directing investment to communities on the frontlines of conservation.</p><p>The Equitable Earth Standard is supported by a coalition of the world’s leading forest carbon project developers, NGOs, and technical experts – including specialists in remote sensing, GIS, and satellite monitoring, as well as forest carbon scientists and climate data analysts. These experts play a critical role in measuring carbon storage, tracking deforestation trends, and ensuring the scientific integrity of Equitable Earth projects’ emissions reductions.</p><p><u>Global context</u></p><p>The world faces an escalating climate and biodiversity crisis driven by deforestation and ecosystem destruction. Indigenous Peoples have been the foremost protectors of the world’s forests for millennia, yet they receive only a fraction of the financial support needed to continue their essential role in conservation. The initiative announced today recognizes Indigenous ecological expertise through direct investment, helping to provide the financial resources necessary for communities to fund their own goals and to continue protecting the world’s most vital ecosystems—benefiting not just communities, but the entire planet.</p><p>The announcement took place at Global Citizen NOW on <span class="xn-chron">30 April 2025</span>, in <span class="xn-location">New York City</span>, where global leaders, financial institutions, Indigenous representatives, and conservation experts gathered to advance solutions for climate and social impact.</p><p>As the world prepares for <span class="xn-money">COP30</span> in Belém, <span class="xn-location">Brazil</span>, this initiative fully aligns with President Lula’s ambition to raise major investment to protect the Amazon – again demonstrating the critical role of Indigenous-led conservation and private sector finance in achieving global climate goals.</p><p><b>About Everland<br /></br></b>Everland is a specialized conservation marketing organization in the climate change mitigation business that exclusively represents the Voluntary Carbon Market’s largest portfolio of high-impact, community-centered, forest conservation (REDD+) projects. Through these projects, Everland brings together communities and corporations in common cause to protect some of the world’s most important and vulnerable forests.<br /></br><u><a href="https://c212.net/c/link/?t=0&l=en&o=4417357-1&h=507530499&u=http%3A%2F%2Fwww.everland.earth%2F&a=everland.earth" rel="nofollow" target="_blank">everland.earth</a></u></p><p><b>About Equitable Earth<br /></br></b>Equitable Earth is a groundbreaking standard that integrates technical innovation and conservation best practices with the priorities of Indigenous Peoples, traditional communities, and Global South governments to stop deforestation and secure the long-term protection of the world’s vital ecosystems. By meeting market demands for high integrity, radical transparency, and robust science, Equitable Earth ensures that those leading the protection of forests receive the necessary investment to sustain durable conservation for generations to come.<br /></br><u><a href="https://c212.net/c/link/?t=0&l=en&o=4417357-1&h=3823053305&u=https%3A%2F%2Feq-earth.com%2F&a=eq-earth.com" rel="nofollow" target="_blank">eq-earth.com</a></u></p><p><b>About Panthera<br /></br></b>Founded in 2006, Panthera is devoted to preserving wild cats and their critical role in the world’s ecosystems. Panthera’s team of leading biologists, law enforcement experts and wild cat advocates develop innovative strategies based on the best available science to protect cheetahs, jaguars, leopards, lions, pumas, snow leopards, tigers and the 33 small cat species and their vast landscapes. In 39 countries around the world, Panthera works with a wide variety of stakeholders to reduce or eliminate the most pressing threats to wild cats—securing their future, and ours. Visit<a href="https://c212.net/c/link/?t=0&l=en&o=4417357-1&h=2180227624&u=https%3A%2F%2Fwww.panthera.org%2F&a=%C2%A0" rel="nofollow" target="_blank"> </a><u><a href="https://c212.net/c/link/?t=0&l=en&o=4417357-1&h=4081520572&u=https%3A%2F%2Fwww.panthera.org%2F&a=Panthera.org" rel="nofollow" target="_blank">Panthera.org</a></u></p><p><b>About the Jaguar Corridor Initiative<br /></br></b>Panthera’s Jaguar Corridor Initiative is an ambitious conservation strategy that aims to preserve the physical and genetic connectivity of jaguars throughout their 6 million km<sup>2</sup> range, from <span class="xn-location">Mexico</span> to <span class="xn-location">Argentina</span>. Recognizing that jaguars require vast territories to thrive, Panthera works with governments, local communities, and other stakeholders to establish a network of safe passages, or corridors, to ensure connectivity among core jaguar populations. Learn more about the<a href="https://c212.net/c/link/?t=0&l=en&o=4417357-1&h=1497642339&u=https%3A%2F%2Fpanthera.org%2Fpantheras-jaguar-program&a=%C2%A0" rel="nofollow" target="_blank"> </a><u><a href="https://c212.net/c/link/?t=0&l=en&o=4417357-1&h=4271028648&u=https%3A%2F%2Fpanthera.org%2Fpantheras-jaguar-program&a=Jaguar+Corridor+Initiative" rel="nofollow" target="_blank">Jaguar Corridor Initiative</a>.</u></p><p id="PURL"><img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN77168&sd=2025-04-30" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/everland-in-partnership-with-bnp-paribas-announces-50-million-capital-markets-initiative-to-launch-first-indigenous-led-amazon-forest-conservation-projects-under-equitable-earth-standard-302443311.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/everland-in-partnership-with-bnp-paribas-announces-50-million-capital-markets-initiative-to-launch-first-indigenous-led-amazon-forest-conservation-projects-under-equitable-earth-standard-302443311.html</a></p><p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN77168&Transmission_Id=202504301700PR_NEWS_EURO_ND__EN77168&DateId=20250430" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>]]></content:encoded> </item> <item> <title>Markel Group reports 2025 first quarter results</title> <link>https://thenewsthisweek.co.uk/markel-group-reports-2025-first-quarter-results-19169/</link> <dc:creator><![CDATA[PR Newswire]]></dc:creator> <pubDate>Wed, 30 Apr 2025 20:50:00 +0000</pubDate> <category><![CDATA[Brand Post]]></category> <guid isPermaLink="false">https://thenewsthisweek.co.uk/markel-group-reports-2025-first-quarter-results-19169/</guid> <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="54" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/05/markel-group-reports-2025-first-quarter-results.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>RICHMOND, Va., April 30, 2025 /PRNewswire/ — Markel Group Inc. (NYSE:MKL) today reported its financial results for the first quarter of 2025. The Company also announced today it filed its Form 10-Q for the quarter ended March 31, 2025 with the Securities and Exchange Commission. “The first quarter was a productive one at Markel Group. […]]]></description> <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="54" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/05/markel-group-reports-2025-first-quarter-results.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div><p><span class="legendSpanClass"><span class="xn-location">RICHMOND, Va.</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 30, 2025</span></span> /PRNewswire/ — Markel Group Inc. (NYSE:MKL) today reported its financial results for the first quarter of 2025. The Company also announced today it filed its Form 10-Q for the quarter ended <span class="xn-chron">March 31, 2025</span> with the Securities and Exchange Commission.</p><div dir="ltr" id="prni_dvprnejpg9ee7left" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="Markel Group logo" id="prnejpg9ee7left" src="https://mma.prnewswire.com/media/2077105/Markel_Group_Logo.jpg" title="Markel Group logo"></img></div><p>“The first quarter was a productive one at Markel Group. Our cornerstone insurance business moved along its path to better. We experienced a lower than initially anticipated impact from the <span class="xn-location">California</span> wildfires. Excluding that impact, our combined ratio returned to the low nineties. We also elevated <span class="xn-person">Simon Wilson</span> as the new leader of our Markel Insurance business. Simon is a proven leader and winner – and he has a clear vision for how to profitably grow that business. Finally, while the strong tailwinds of the past few years have eased, results within our Ventures businesses continued to hold up well,” said <span class="xn-person">Tom Gayner</span>, Chief Executive Officer of Markel Group.</p><p>The following table presents the Company’s summary financial data, by engine, for the three months ended <span class="xn-chron">March 31, 2025</span> and 2024.</p><div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tr><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen3" colspan="3" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Three Months Ended March 31, </span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><i><u>(dollars in thousands, except per share amounts)</u></i></span></p></td><td class="prngen5" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>2025</b></span></p></td><td class="prngen6" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen5" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2024</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Operating revenues:</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml10"><span class="prnews_span">Insurance</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 2,187,813</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 2,185,718</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml10"><span class="prnews_span">Investments:</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml30"><span class="prnews_span">Net investment income</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>235,601</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">217,204</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml30"><span class="prnews_span">Net investment gains (losses)</span></p></td><td class="prngen7" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>(149,071)</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">902,281</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml30"><span class="prnews_span">Other</span></p></td><td class="prngen8" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>(4,610)</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">20,846</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml10"><span class="prnews_span">Total Investments</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>81,920</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">1,140,331</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml10"><span class="prnews_span">Markel Ventures</span></p></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>1,129,372</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">1,140,606</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml40"><span class="prnews_span">Total operating revenues</span></p></td><td class="prngen10" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 3,399,105</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen10" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 4,466,655</span></p></td></tr><tr><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Operating income:</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml10"><span class="prnews_span">Insurance <sup>(1)</sup></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 145,036</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 135,825</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml10"><span class="prnews_span">Investments:</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml30"><span class="prnews_span">Net investment income</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>235,601</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">217,204</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml30"><span class="prnews_span">Net investment gains (losses)</span></p></td><td class="prngen7" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>(149,071)</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">902,281</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml30"><span class="prnews_span">Other</span></p></td><td class="prngen8" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>(4,610)</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">20,846</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml10"><span class="prnews_span">Total Investments</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>81,920</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">1,140,331</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml10"><span class="prnews_span">Markel Ventures</span></p></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>102,510</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">103,915</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml40"><span class="prnews_span">Consolidated segment operating income <sup>(2)</sup></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>329,466</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">1,380,071</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml10"><span class="prnews_span">Amortization of acquired intangible assets</span></p></td><td class="prngen7" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>(46,942)</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen7" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">(44,285)</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml40"><span class="prnews_span">Total operating income</span></p></td><td class="prngen11" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 282,524</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen11" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 1,335,786</span></p></td></tr><tr><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Comprehensive income to shareholders</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 347,670</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 908,385</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Diluted net income per common share</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 12.08</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 75.43</span></p></td></tr><tr><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Combined ratio</span></p></td><td class="prngen12" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>95.8 %</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen12" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">95.2 %</span></p></td></tr></table></div><div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tr><td class="prngen13" colspan="1" rowspan="1"></br></td></tr><tr><td class="prngen13" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><sup>(1)</sup> See “Supplemental Financial Information” for the components of our Insurance engine operating income.</span></p></td></tr><tr><td class="prngen13" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><sup>(2)</sup> See “Non-GAAP Financial Measures” for additional information on this non-GAAP measure.</span></p></td></tr></table></div><p>Highlights of results from the quarter:</p><ul type="disc"><li>Operating revenues and operating income for the three months ended <span class="xn-chron">March 31, 2025</span> decreased compared to the same period of 2024, largely driven by unfavorable market value movements within our equity portfolio in 2025 compared to significant favorable movements in 2024. Generally accepted accounting principles (GAAP) require that we include unrealized gains and losses on equity securities in net income. This may lead to short-term volatility in revenues and operating income that temporarily obscures our underlying operating performance.</li><li>Net investment income increased 8%, reflecting a higher yield and higher average holdings of fixed maturity securities in 2025 compared to 2024.</li><li>Underwriting results for the first quarter of 2025 included <span class="xn-money">$80.6 million</span> of underwriting losses, or four points on the consolidated combined ratio, attributed to the January wildfires in southern <span class="xn-location">California</span> (California Wildfires) compared to no catastrophe losses in the first quarter of 2024.</li><li>Excluding the impact from the California Wildfires, our consolidated combined ratio for the three months ended <span class="xn-chron">March 31, 2025</span> decreased compared to the same period of 2024, primarily due to more favorable development on prior accident years loss reserves in 2025 compared to 2024.</li><li>Markel Ventures operating revenues declined 1% compared to the first quarter of 2024. The impact of decreased demand at certain of our businesses was largely offset by the contribution of revenues from our acquisitions of Valor and EPI, which totaled <span class="xn-money">$28.1 million</span> during the first quarter of 2025.</li></ul><p>We believe our financial performance is most meaningfully measured over longer periods of time, which tends to mitigate the effects of short-term volatility and also aligns with the long-term perspective we apply to operating our businesses and making investment decisions. The following table presents a long-term view of our performance.</p><div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tr><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen14" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Three Months <br /></br>Ended March 31, </span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen14" colspan="7" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Years Ended December 31,</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><i><u>(dollars in thousands)</u></i></span></p></td><td class="prngen15" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>2025</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen15" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2024</span></p></td><td class="prngen6" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen5" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2023</span></p></td><td class="prngen6" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen5" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2022</span></p></td><td class="prngen6" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen5" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2021</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Operating income (loss):</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml20"><span class="prnews_span">Insurance <sup>(1)</sup></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 145,036</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 601,002</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 348,145</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 928,709</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 718,800</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml20"><span class="prnews_span">Investments <sup>(2)</sup></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>81,920</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2,772,950</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2,241,419</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen7" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">(1,167,548)</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2,353,124</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml20"><span class="prnews_span">Markel Ventures</span></p></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>102,510</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">520,082</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">519,878</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">404,281</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen9" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">330,120</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml40"><span class="prnews_span">Consolidated segment operating income <sup>(3)</sup></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>329,466</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">3,894,034</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">3,109,442</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">165,442</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">3,402,044</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml20"><span class="prnews_span">Amortization and impairment</span></p></td><td class="prngen8" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>(46,942)</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen8" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">(181,472)</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen8" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">(180,614)</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen8" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">(258,778)</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen8" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">(160,539)</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml40"><span class="prnews_span">Total operating income (loss)</span></p></td><td class="prngen10" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 282,524</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen10" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 3,712,562</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen10" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 2,928,828</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen16" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ (93,336)</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen10" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 3,241,505</span></p></td></tr><tr><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Net investment gains (losses) <sup>(2)</sup></span></p></td><td class="prngen7" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ (149,071)</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 1,807,219</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 1,524,054</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen7" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ (1,595,733)</span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 1,978,534</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Compound annual growth rate in closing stock price per share from December 31, 2020 to March 31, 2025</span></p></td><td class="prngen12" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>15 %</b></span></p></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen2" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr></table></div><div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tr><td class="prngen17" colspan="1" rowspan="1"></br></td><td class="prngen17" colspan="1" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><sup>(1)</sup> </span></p></td><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">See “Supplemental Financial Information” for the components of our Insurance engine operating income.</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><sup>(2)</sup> </span></p></td><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Investments engine operating income includes net investment gains (losses), which are primarily comprised of unrealized gains and losses on equity securities.</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><sup>(3)</sup> </span></p></td><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">See “Non-GAAP Financial Measures” for additional information on this non-GAAP measure.</span></p></td></tr></table></div><p class="prntac">* * * * * * * *</p><p>A copy of our Form 10-Q is available on our website at <u><a href="https://c212.net/c/link/?t=0&l=en&o=4417027-1&h=3509106512&u=https%3A%2F%2Fwww.mklgroup.com%2F&a=mklgroup.com" rel="nofollow" target="_blank">mklgroup.com</a></u>, under Investor Relations-Financials, or on the SEC website at <u><a href="https://c212.net/c/link/?t=0&l=en&o=4417027-1&h=3109855067&u=https%3A%2F%2Fwww.sec.gov%2F&a=www.sec.gov" rel="nofollow" target="_blank">www.sec.gov</a></u>. Readers are urged to review the Form 10-Q for a more complete discussion of our financial performance. Our quarterly conference call, which will involve discussion of our financial results and business developments and may include forward-looking information, will be held <span class="xn-chron">Thursday, May 1, 2025</span>, beginning at <span class="xn-chron">9:30 a.m. (Eastern Time)</span>. Investors, analysts and the general public may listen to the call via live webcast at <u><a href="https://c212.net/c/link/?t=0&l=en&o=4417027-1&h=1172920436&u=https%3A%2F%2Fir.mklgroup.com%2Foverview%2F&a=ir.mklgroup.com" rel="nofollow" target="_blank">ir.mklgroup.com</a></u>. The call may be accessed telephonically by dialing (888) 660-9916 in the U.S., or (646) 960-0452 internationally, and providing Conference ID: 4614568. A replay of the call will be available on our website approximately one hour after the conclusion of the call. Any person needing additional information can contact Markel Group’s Investor Relations Department at <u><a href="mailto:IR@markel.com" rel="nofollow" target="_blank">IR@markel.com</a></u>.</p><p>Additionally, we will be discussing financial results and related business and investments updates at our shareholders meeting on <span class="xn-chron">May 21, 2025</span> at the <span class="xn-org">University of Richmond’s</span> Robins Center at <span class="xn-chron">2:00 p.m. (Eastern Time)</span>. The shareholders meeting will be part of a two-day event we call the <span class="xn-location">Reunion</span>, which is open to shareholders, employees, and friends of Markel Group. More information on the agenda and registration for the <span class="xn-location">Reunion</span> is available at <a href="https://c212.net/c/link/?t=0&l=en&o=4417027-1&h=1406656241&u=https%3A%2F%2Fmklreunion.com%2F&a=mklreunion.com" rel="nofollow" target="_blank"><u>mklreunion.com</u></a>.</p><p><b>Supplemental Financial Information<br /></br></b>The following table presents the components of our Insurance engine operating income.</p><div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tr><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen3" colspan="3" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Three Months Ended March 31, </span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen3" colspan="7" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Years Ended December 31,</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><i><u>(dollars in thousands)</u></i></span></p></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>2025</b></span></p></td><td class="prngen20" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2024</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2024</span></p></td><td class="prngen20" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2023</span></p></td><td class="prngen20" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2022</span></p></td><td class="prngen20" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2021</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Insurance operating income (loss):</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml20"><span class="prnews_span">Insurance segment</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 53,216</b></span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 107,310</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 421,885</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 162,176</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 549,871</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 696,413</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml20"><span class="prnews_span">Reinsurance segment</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>25,033</b></span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">12,010</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen12" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">(5,363)</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen12" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">(19,265)</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">83,859</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen12" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">(55,129)</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml20"><span class="prnews_span">Other insurance operations</span></p></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>66,787</b></span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">16,505</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">184,480</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">205,234</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">294,979</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">77,516</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml40"><span class="prnews_span">Insurance</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 145,036</b></span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 135,825</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 601,002</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 348,145</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 928,709</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 718,800</span></p></td></tr></table></div><p><b>Non-GAAP Financial Measures<br /></br></b>Consolidated segment operating income is a non-GAAP financial measure as it represents the total of the segment operating income from each of our operating segments and excludes items included in operating income. Consolidated segment operating income excludes amortization of acquired intangible assets and goodwill impairments arising from purchase accounting as they do not represent costs of operating the underlying businesses. The following table reconciles operating income to consolidated segment operating income.</p><div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tr><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen3" colspan="3" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Three Months Ended March 31, </span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen3" colspan="7" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Years Ended December 31,</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><i><u>(dollars in thousands)</u></i></span></p></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>2025</b></span></p></td><td class="prngen20" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2024</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2024</span></p></td><td class="prngen20" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2023</span></p></td><td class="prngen20" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2022</span></p></td><td class="prngen20" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen19" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">2021</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Operating income (loss)</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 282,524</b></span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 1,335,786</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 3,712,562</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 2,928,828</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen12" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ (93,336)</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 3,241,505</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml20"><span class="prnews_span">Amortization of acquired intangible assets</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>46,942</b></span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">44,285</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">181,472</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">180,614</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">178,778</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">160,539</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml20"><span class="prnews_span">Impairment of goodwill</span></p></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>—</b></span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">—</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">—</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">—</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">80,000</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen21" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">—</span></p></td></tr><tr><td class="prngen4" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">Consolidated segment operating income</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>$ 329,466</b></span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 1,380,071</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 3,894,034</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 3,109,442</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 165,442</span></p></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"></br></td><td class="prngen18" colspan="1" nowrap="nowrap" rowspan="1"><p class="prnml4"><span class="prnews_span">$ 3,402,044</span></p></td></tr></table></div><p><b>About Markel Group<br /></br></b>Markel Group Inc. is a diverse family of companies that includes everything from insurance to bakery equipment, building supplies, houseplants, and more. The leadership teams of these businesses operate with a high degree of independence, while at the same time living the values that we call the Markel Style. Our specialty insurance business sits at the core of our company. Through decades of sound underwriting, the insurance team has provided the capital base from which we built a system of businesses and investments that collectively increase Markel Group’s durability and adaptability. It’s a system that provides diverse income streams, access to a wide range of investment opportunities, and the ability to efficiently move capital to the best ideas across the company. Most importantly though, this system enables each of our businesses to advance our shared goal of helping our customers, associates, and shareholders win over the long term. Visit <u><a href="https://c212.net/c/link/?t=0&l=en&o=4417027-1&h=3509106512&u=https%3A%2F%2Fwww.mklgroup.com%2F&a=mklgroup.com" rel="nofollow" target="_blank">mklgroup.com</a></u> to learn more.</p><p><b>Cautionary Statement<br /></br></b>Certain of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Statements that are not historical facts, including statements about our beliefs, plans or expectations, are forward-looking statements. These statements are based on our current plans, estimates and expectations. There are risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by such statements. Factors that may cause actual results to differ are often presented with the forward-looking statements themselves. Additional factors that could cause actual results to differ from those predicted are set forth in our Annual Report on Form 10-K for the year ended <span class="xn-chron">December 31, 2024</span>, including under “Business Overview,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Safe Harbor and Cautionary Statement,” and “Quantitative and Qualitative Disclosures About Market Risk,” and in our Quarterly Report on Form 10-Q for the quarter ended <span class="xn-chron">March 31, 2025</span>, including under “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Safe Harbor and Cautionary Statement,” “Quantitative and Qualitative Disclosures About Market Risk,” and “Risk Factors”. We assume no obligation to update this release (including any forward-looking statements) as a result of new information, developments, or otherwise. This release speaks only as of the date issued.</p><p>Logo – <a href="https://c212.net/c/link/?t=0&l=en&o=4417027-1&h=138831048&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2077105%2FMarkel_Group_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2077105%2FMarkel_Group_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/2077105/Markel_Group_Logo.jpg</a></p><p id="PURL"><img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN76844&sd=2025-04-30" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/markel-group-reports-2025-first-quarter-results-302443322.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/markel-group-reports-2025-first-quarter-results-302443322.html</a></p><p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN76844&Transmission_Id=202504301650PR_NEWS_EURO_ND__EN76844&DateId=20250430" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>]]></content:encoded> </item> <item> <title>Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference</title> <link>https://thenewsthisweek.co.uk/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2025-healthcare-conference-19171/</link> <dc:creator><![CDATA[PR Newswire]]></dc:creator> <pubDate>Wed, 30 Apr 2025 20:15:00 +0000</pubDate> <category><![CDATA[Brand Post]]></category> <guid isPermaLink="false">https://thenewsthisweek.co.uk/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2025-healthcare-conference-19171/</guid> <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="24" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/05/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2025-healthcare-conference.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>DUBLIN, April 30, 2025 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on Wednesday, May 14, 2025, at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST. An audio webcast of the fireside […]]]></description> <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="24" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/05/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2025-healthcare-conference.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div><p><span class="legendSpanClass"><span class="xn-location">DUBLIN</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 30, 2025</span></span> /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on <span class="xn-chron">Wednesday, May 14, 2025</span>, at <span class="xn-chron">10:00 a.m. PT</span> / <span class="xn-chron">1:00 p.m. ET</span> / <span class="xn-chron">6:00 p.m. IST</span>.</p><p>An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at <a href="https://c212.net/c/link/?t=0&l=en&o=4416239-1&h=1546307479&u=https%3A%2F%2Finvestor.jazzpharma.com%2Finvestors%2Fevents-presentations&a=https%3A%2F%2Finvestor.jazzpharma.com%2Finvestors%2Fevents-presentations" rel="nofollow" target="_blank">https://investor.jazzpharma.com/investors/events-presentations</a>. A replay of the webcast will be archived on the website for 30 days.</p><p><b><u>About Jazz Pharmaceuticals<br /></br></u></b>Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in <span class="xn-location">Dublin, Ireland</span> with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit <a href="https://c212.net/c/link/?t=0&l=en&o=4416239-1&h=562433519&u=http%3A%2F%2Fwww.jazzpharmaceuticals.com%2F&a=www.jazzpharmaceuticals.com" rel="nofollow" target="_blank">www.jazzpharmaceuticals.com</a> for more information.</p><p><b>Contacts:<br /></br></b><b>Investors: <br /></br></b><span class="xn-person">Jeff Macdonald</span><br /></br>Executive Director, Investor Relations<br /></br>Jazz Pharmaceuticals plc<br /></br><a href="mailto:InvestorInfo@jazzpharma.com" rel="nofollow" target="_blank">InvestorInfo@jazzpharma.com</a><br /></br><span class="xn-location">Ireland</span> +353 1 634 3211<br /></br>U.S. +1 650 496 2717</p><p><b>Media:</b><br /></br><span class="xn-person">Kristin Bhavnani</span><br /></br>Head of Global Corporate Communications<br /></br>Jazz Pharmaceuticals plc<br /></br><a href="mailto:CorporateAffairsMediaInfo@jazzpharma.com" rel="nofollow" target="_blank">CorporateAffairsMediaInfo@jazzpharma.com</a><br /></br><span class="xn-location">Ireland</span> +353 1 637 2141<br /></br>U.S. +1 215 867 4948</p><div dir="ltr" id="prni_dvprnejpgc1cfleft" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="Jazz Pharmaceuticals Logo" id="prnejpgc1cfleft" src="https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg" title="Jazz Pharmaceuticals Logo"></img></div><p>Logo – <span><a href="https://c212.net/c/link/?t=0&l=en&o=4416239-1&h=2571902811&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F272253%2FJazz_Pharmaceuticals_New_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F272253%2FJazz_Pharmaceuticals_New_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg</a> </span></p><p id="PURL"><img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN76046&sd=2025-04-30" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2025-healthcare-conference-302442987.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2025-healthcare-conference-302442987.html</a></p><p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN76046&Transmission_Id=202504301615PR_NEWS_EURO_ND__EN76046&DateId=20250430" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>]]></content:encoded> </item> <item> <title>Tetragon Financial Group Limited Announcement of Dividend and Update Regarding Equitix</title> <link>https://thenewsthisweek.co.uk/tetragon-financial-group-limited-announcement-of-dividend-and-update-regarding-equitix-19173/</link> <dc:creator><![CDATA[PR Newswire]]></dc:creator> <pubDate>Wed, 30 Apr 2025 19:29:00 +0000</pubDate> <category><![CDATA[Brand Post]]></category> <guid isPermaLink="false">https://thenewsthisweek.co.uk/tetragon-financial-group-limited-announcement-of-dividend-and-update-regarding-equitix-19173/</guid> <description><![CDATA[LONDON, April 30, 2025 /PRNewswire/ — Dividend Announcement: On 30 April 2025, the Board of Directors of Tetragon declared a dividend of U.S.$ 0.11 (11.00 cents) per share in respect of the first quarter of 2025. The ex-dividend date is 5 May 2025. The record date is 6 May 2025. Payment of the dividend will […]]]></description> <content:encoded><![CDATA[<p><span class="legendSpanClass"><span class="xn-location">LONDON</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 30, 2025</span></span> /PRNewswire/ —</p><p>Dividend Announcement:</p><p>On <span class="xn-chron">30 April 2025</span>, the Board of Directors of Tetragon declared a dividend of U.S.<span class="xn-money">$ 0.11</span> (<span class="xn-money">11.00 cents</span>) per share in respect of the first quarter of 2025. The ex-dividend date is <span class="xn-chron">5 May 2025</span>. The record date is <span class="xn-chron">6 May 2025</span>. Payment of the dividend will take place from <span class="xn-chron">30 May 2025</span>.</p><p>Tetragon’s website (<a href="https://c212.net/c/link/?t=0&l=en&o=4417418-1&h=1320152850&u=http%3A%2F%2Fwww.tetragoninv.com%2F&a=www.tetragoninv.com" rel="nofollow" target="_blank">www.tetragoninv.com</a>) includes information on Tetragon’s Optional Stock Dividend Plan for those shareholders electing to receive dividends in the form of Tetragon shares. Shareholders may elect to receive dividends in the form of Tetragon shares by making a dividend share election up to <span class="xn-chron">16 May 2025</span>. If no election is made, the dividend will be paid in cash from <span class="xn-chron">30 May 2025</span>.</p><p>Cash dividends may be received in Sterling by those shareholders making a dividend currency election up to <span class="xn-chron">16 May 2025</span>. If no election is made, the dividend will be paid in U.S. dollars from <span class="xn-chron">30 May 2025</span>.</p><p>Update Regarding Equitix:</p><p>Following on from our discussion regarding Equitix in our 2024 Annual Report and in our <span class="xn-chron">14 October 2024</span> statement regarding press speculation, we note that the continued strong performance of Equitix, as well as other businesses on the platform, has enhanced the attractiveness of individual business transactions and other strategic opportunities as important ways of realising and hopefully accelerating the value inherent in TFG Asset Management. As such, the strategy for TFG Asset Management with respect to Equitix includes continuing to engage with strategic partners and financial advisors to explore options for executing on transactions or partnerships that would take advantage of this value enhancement. Although we do not expect to consummate a transaction with respect to Equitix in the immediate term, our strategy remains unchanged.</p><p>About Tetragon:</p><p>Tetragon is a Guernsey closed-ended investment company. Its non-voting shares are listed on Euronext in <span class="xn-location">Amsterdam</span>, a regulated market of Euronext Amsterdam N.V., and also traded on the Specialist Fund Segment of the Main Market of the London Stock Exchange. Our investment manager is Tetragon Financial Management LP. Find out more at <a href="https://c212.net/c/link/?t=0&l=en&o=4417418-1&h=1320152850&u=http%3A%2F%2Fwww.tetragoninv.com%2F&a=www.tetragoninv.com" rel="nofollow" target="_blank">www.tetragoninv.com</a>.</p><p>Tetragon’s non-voting shares are subject to restrictions on ownership by U.S. persons and are not intended for European retail investors.</p><p>Please see: <a href="https://c212.net/c/link/?t=0&l=en&o=4417418-1&h=137369741&u=https%3A%2F%2Fwww.tetragoninv.com%2Fshareholders%2Fadditional-information&a=https%3A%2F%2Fwww.tetragoninv.com%2Fshareholders%2Fadditional-information" rel="nofollow" target="_blank">https://www.tetragoninv.com/shareholders/additional-information</a>.</p><p>Tetragon Investor Relations:<br /></br><span class="xn-person">Yuko Thomas</span><br /></br><a href="mailto:ir@tetragoninv.com" rel="nofollow" target="_blank">ir@tetragoninv.com</a></p><p>Press Inquiries:<br /></br>Prosek Partners<br /></br><a href="mailto:pro-tetragon@prosek.com" rel="nofollow" target="_blank">pro-tetragon@prosek.com</a><br /></br>U.K. +44 20 3890 9193<br /></br>U.S. +1 212 279 3115</p><p><b><i>This release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (2014/596/EU), or EU MAR, and of the UK version of EU MAR as it forms part of UK law by virtue of the European Union (Withdrawal) Act (as amended).</i></b></p><p>This release does not contain or constitute an offer to sell or a solicitation of an offer to purchase securities in the United States or any other jurisdiction. The securities of Tetragon have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in <span class="xn-location">the United States</span> or to U.S. persons unless they are registered under applicable law or exempt from registration. Tetragon does not intend to register any portion of its securities in <span class="xn-location">the United States</span> or to conduct a public offer of securities in <span class="xn-location">the United States</span>. In addition, Tetragon has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended, and investors will not be entitled to the benefits of such Act. Tetragon is registered in the public register of the Netherlands Authority for the Financial Markets (<i>Autoriteit Financiële Markten</i>) under Section 1:107 of the Dutch Financial Markets Supervision Act as an alternative investment fund from a designated state.</p><p id="PURL"><img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN77232&sd=2025-04-30" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/tetragon-financial-group-limited-announcement-of-dividend-and-update-regarding-equitix-302443215.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/tetragon-financial-group-limited-announcement-of-dividend-and-update-regarding-equitix-302443215.html</a></p><p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN77232&Transmission_Id=202504301529PR_NEWS_EURO_ND__EN77232&DateId=20250430" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>]]></content:encoded> </item> <item> <title>Fluorescence Microscopy Market to Reach $1.3 Billion by 2029</title> <link>https://thenewsthisweek.co.uk/fluorescence-microscopy-market-to-reach-1-3-billion-by-2029-19174/</link> <dc:creator><![CDATA[PR Newswire]]></dc:creator> <pubDate>Wed, 30 Apr 2025 19:25:00 +0000</pubDate> <category><![CDATA[Brand Post]]></category> <guid isPermaLink="false">https://thenewsthisweek.co.uk/fluorescence-microscopy-market-to-reach-1-3-billion-by-2029-19174/</guid> <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="36" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/05/fluorescence-microscopy-market-to-reach-1-3-billion-by-2029.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>“Life Sciences Drive Fluorescence Microscopy Market Growth Amid Rising Disease Prevalence and Technological Advances” BOSTON, April 30, 2025 /PRNewswire/ — According to the latest study from BCC Research, the “Global Fluorescence Microscopy Market” is expected to grow from $968.5 million in 2024 to $1.3 billion by the end of 2029, at a compound annual growth rate […]]]></description> <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="36" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/05/fluorescence-microscopy-market-to-reach-1-3-billion-by-2029.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div><p><b><i>“Life Sciences Drive Fluorescence Microscopy Market Growth Amid Rising Disease Prevalence and Technological Advances”</i></b></p><p><span class="legendSpanClass"><span class="xn-location">BOSTON</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 30, 2025</span></span> /PRNewswire/ — According to the latest study from BCC Research, the “<b><a href="https://www.bccresearch.com/market-research/instrumentation-and-sensors/global-fluorescence-microscopy-market-report.html?utm_source=PRNWIAS134B&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">Global Fluorescence Microscopy Market</a></b>” is expected to grow from <span class="xn-money">$968.5 million</span> in 2024 to <span class="xn-money">$1.3 billion</span> by the end of 2029, at a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2024 to 2029.</p><div dir="ltr" id="prni_dvprnejpg970bleft" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="BCC Research" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2183242%2FBCC_Research_Logo.jpg" id="prnejpg970bleft" src="https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg" title="BCC Research"></img></div><p>This report covers product types such as upright and inverted microscopes and segments the market by illumination method, component, technology, and end-use. It assesses current market status, forecasts growth for the next six years, and analyzes market drivers, restraints, and opportunities.</p><p>It also profiles leading companies, analyzing their business segments, financials, product portfolios, and recent developments while covering emerging technologies, patent analysis and ESG trends.</p><p><b>The factors driving the market’s growth include:</b></p><p><b>Technological Advances: </b>Innovations such as super-resolution and light sheet fluorescence microscopy enhance visualization and analysis of cellular structures.</p><p><b>Personalized Medicine Research: </b>Fluorescence microscopy aids in understanding cellular and molecular processes, which is crucial for developing targeted therapies.</p><p><b>Understanding Cellular Processes</b>: Real-time observation of cellular mechanisms helps in medical research and biotechnology advances.</p><p><b>Research Funding</b>: Increased funding supports new technologies, equipment, and researcher training.</p><p><b>Miniaturization</b>: Advances in semiconductor technology are leading to smaller, more efficient microscopy equipment.</p><p><b>Request a sample copy of </b><b><a href="https://www.bccresearch.com/market-research/instrumentation-and-sensors/global-fluorescence-microscopy-market-report.html?ro=yes&utm_source=PRNWIAS134B&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">the global market for fluorescence microscopy report</a></b><b>.</b></p><p><b>Report Synopsis</b></p><div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tr><td class="prnpr2 prnpl2 prnvab prncbts prnbrbrs prnbbbs prnbsbls" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Report Metric</b></span></p></td><td class="prnpr2 prnpl2 prnvab prncbts prnbrbrs prnbbbs prnsblb1" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Details</b></span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Base year considered</span></p></td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">2023</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Forecast period considered</span></p></td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">2024-2029</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Base year market size</span></p></td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$911.2 million</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Market size forecast</span></p></td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">$1.3 billion</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Growth rate</span></p></td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">CAGR of 6.5% for the forecast period of 2024-2029</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Segments covered</span></p></td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Product type, illumination method, component, technology, end use, and region</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Regions covered</span></p></td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">North America, Europe, Asia-Pacific, and the Rest of the World</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Countries covered</span></p></td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, China, India, and Japan</span></p></td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Market drivers</span></p></td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">• Technological advances.</span></p><p class="prnml4"><span class="prnews_span">• Increasing research in the field of personalized medicines.</span></p><p class="prnml4"><span class="prnews_span">• Increasing demand for improved understanding of cellular process.</span></p><p class="prnml4"><span class="prnews_span">• Increasing availability of research funds in life sciences.</span></p><p class="prnml4"><span class="prnews_span">• Growing miniaturization due to advances in semiconductor technology.</span></p></td></tr></table></div><p> </p><p><i><b>Interesting facts:</b></i></p><ul type="disc"><li><i>The fluorescence microscopy market is rapidly evolving with new technologies. Many companies are adopting these advances through new product launches, acquisitions, collaborations, and partnerships. For example, in 2023, Nikon introduced the AX R MP with NSPARC, a super-resolution multiphoton confocal microscope that enhances detection sensitivity and resolution in deep tissue samples.</i></li><li><i>In addition to public companies, private firms such as Etaluma, Euromex, PicoQuant, Thorlabs and Meiji Techno are also active in the market. Etaluma, for instance, offers affordable inverted fluorescence microscopes to a wide range of customers. Start-ups such as ONI, Abberior Instruments America LLC and Alpenglow Biosciences are developing advanced microscopes for live cell imaging, supporting the growing demand for biomedical research.</i></li></ul><p><i><b>Emerging startups:</b></i></p><p><i><b>ONI</b></i><i>: Based in <span class="xn-location">Oxford, U.K.</span>, ONI was established in 2016. The company produces resolution microscopes for use in research, industry, and medicine. With applications in neuroscience, extracellular vesicles (EVs), pathogens and immuno-oncology, cell phenotyping, and epigenetic mapping, the company offers NimOS and CODI software, an EV profiler kit, and Nanoimager, a desktop super-resolution microscope that can see, track, and image individual molecules in living cells with 20 nm resolution. </i></p><p><i><b>Abberior Instruments America LLC</b></i><i>: Abberior Instruments, founded in 2016, is a leader in super-resolution microscopy and provides imaging systems with spatial resolution for live cell imaging. Its stimulated emission depletion (</i><i>STED) microscopy systems enable researchers to view cellular structures in real time with sub-diffraction-limited resolution. </i></p><p><i><b>Alpenglow Biosciences</b></i><i>: Founded in 2018 as Light Sheet Microscopy Inc., the company offers its 3D i Hybrid Open Top Light Sheet (HOTLS) fluorescent microscope that transforms whole tissue samples into detailed digital models, capturing levels of biological detail beyond standard 2D histology. </i></p><p><i><b>Questions A</b></i><i><b>ddressed:</b></i></p><p><i><b>1. </b></i><i><b>What is the market’s projected size and growth rate?</b></i></p><ul type="disc"><li><i>The fluorescence microscopy market was <span class="xn-money">$ 911.2 million</span> in 2023 and at a CAGR of 6.5% </i><i>over the forecast period, is projected to reach <span class="xn-money">$1.3 billion</span> by the end of 2029.</i></li></ul><p><i><b>2. </b></i><i><b>What factors are driving the growth of the market?</b></i></p><ul type="disc"><li><i>The global market’s growth is due to technological advances and product launches, investments in R&D, increasing demand for personalized medicines, improved understanding of cellular processes, and miniaturization.</i></li></ul><p><i><b>3. </b></i><i><b>What market segments are covered in the report?</b></i></p><ul type="disc"><li><i>The fluorescence microscopy market is segmented by product type, illumination method, component, technology and end-use, and region.</i></li></ul><p><i><b>4. </b></i><i><b>Which product type will be dominant </b></i><i><b>over the forecast period?</b></i></p><ul type="disc"><li><i>The upright microscopy segment will be dominant </i><i>throughout that period.</i></li></ul><p><i><b>5. </b></i><i><b>Which region has the largest market share?</b></i></p><ul type="disc"><li><i><span class="xn-location">North America</span> has the largest share of the market.</i></li></ul><p><b>Market leaders include:</b></p><ul type="disc"><li><b>ACCU-SCOPE INC.</b></li><li><b>BRUKER</b></li><li><b><span class="xn-person">CARL ZEISS AG</span></b></li><li><b>DANAHER CORP.</b></li><li><b>ETALUMA INC.</b></li><li><b>EUROMEX MICROSCOPEN BV</b></li><li><b>HORIBA LTD.</b></li><li><b>KEYENCE CORP.</b></li><li><b>MEIJI TECHNO CO. LTD.</b></li><li><b>MOTIC MICROSCOPES</b></li><li><b>NIKON CORP.</b></li><li><b>OLYMPUS CORP.</b></li><li><b><span class="xn-location">OXFORD</span> INSTRUMENTS</b></li><li><b>PICOQUANT GMBH</b></li><li><b>THERMO FISHER SCIENTIFIC INC.</b></li></ul><p><b>Related reports include:</b></p><p><b><a href="https://www.bccresearch.com/market-research/instrumentation-and-sensors/microscopy-global-market-report.html?utm_source=PRNWIAS134B&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">Microscopy: The Global Market</a></b><b>: This report discusses the different types of microscopes and accessories and their applications. It evaluates the current status of the market, and forecasts growth for the next five years. The report also looks at market drivers, challenges, and opportunities, and includes profiles of leading companies with information on their business segments, financials, products, and recent developments. Additionally, it provides information on emerging technologies, patents, an investment outlook and ESG trends.</b></p><p><b><a href="https://www.bccresearch.com/market-research/biotechnology/live-cell-imaging-market.html?utm_source=PRNWIAS134B&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">Global Live Cell Imaging Market</a></b><b>: This report segments the market by component (instruments, software, consumables, services), technology (time-lapse microscopy, FRET, FRAP, HCS, others), and end users (pharmaceutical and biotech companies, academic research institutes, contract research organizations). The market is divided into four regions: <span class="xn-location">North America</span>, <span class="xn-location">Europe</span>, <span class="xn-location">Asia-Pacific</span>, and Rest of the World. The report also includes a supply chain analysis, an analysis of market opportunities, and profiles of leading companies.</b></p><p><b>Purchase a </b><b><a href="https://www.bccresearch.com/market-research/instrumentation-and-sensors/global-fluorescence-microscopy-market-report.html?utm_source=PRNWIAS134B&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">copy of the report</a></b><b> direct from BCC Research.</b></p><p>For further information or any of these reports or to make a purchase, please contact <a href="mailto:info@bccresearch.com" rel="nofollow" target="_blank">info@bccresearch.com</a>. </p><p><b>About BCC Research</b></p><p>BCC Research market research reports provide objective, unbiased measurement, and assessment of market opportunities. Our experienced industry analysts’ goal is to help you make informed business decisions free of noise and hype.</p><p><b>Contact Us<br /></br></b>Corporate HQ: 50 Milk St., Ste. 16, <span class="xn-location">Boston, MA</span> 02109, <span class="xn-location">USA</span><br /></br>Email: <a href="mailto:info@bccresearch.com" rel="nofollow" target="_blank">info@bccresearch.com</a><br /></br>Phone: +1 781-489-7301</p><p>For media inquiries, email <a href="mailto:press@bccresearch.com" rel="nofollow" target="_blank">press@bccresearch.com</a> or visit our <a href="https://www.bccresearch.com/media?utm_source=PRNWIAS134B&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">media page</a> for access to our market research library.</p><p>Any data and analysis extracted from this press release must be accompanied by a statement identifying <a href="https://www.bccresearch.com/?utm_source=PRNWIAS134B&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">BCC Research LLC</a> as the source and publisher.</p><p>Logo – <a href="https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg</a></p><p id="PURL"><img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN77249&sd=2025-04-30" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/fluorescence-microscopy-market-to-reach-1-3-billion-by-2029--302443210.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/fluorescence-microscopy-market-to-reach-1-3-billion-by-2029–302443210.html</a></p><p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN77249&Transmission_Id=202504301525PR_NEWS_EURO_ND__EN77249&DateId=20250430" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>]]></content:encoded> </item> <item> <title>Global Greenhouse Horticulture Market Surges: Innovations in Plastic and Glass Greenhouses Driving Growth | Valuates Reports</title> <link>https://thenewsthisweek.co.uk/global-greenhouse-horticulture-market-surges-innovations-in-plastic-and-glass-greenhouses-driving-growth-valuates-reports-19154/</link> <dc:creator><![CDATA[PR Newswire]]></dc:creator> <pubDate>Wed, 30 Apr 2025 17:10:00 +0000</pubDate> <category><![CDATA[Brand Post]]></category> <guid isPermaLink="false">https://thenewsthisweek.co.uk/global-greenhouse-horticulture-market-surges-innovations-in-plastic-and-glass-greenhouses-driving-growth-valuates-reports-19154/</guid> <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="29" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/04/global-greenhouse-horticulture-market-surges-innovations-in-plastic-and-glass-greenhouses-driving-growth-valuates-reports.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>BANGALORE, India, April 30, 2025 /PRNewswire/ — Greenhouse Horticulture Market is Segmented by Type (Plastic, Glass), by Application (Ornamentals, Vegetables, Fruit). The Global Greenhouse Horticulture Market revenue was USD 21760 Million in 2022 and is forecast to a readjusted size of USD 31370 Million by 2029 with a CAGR of 5.3% during the review period […]]]></description> <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="29" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/04/global-greenhouse-horticulture-market-surges-innovations-in-plastic-and-glass-greenhouses-driving-growth-valuates-reports.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div><p><span class="legendSpanClass"><span class="xn-location">BANGALORE, India</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 30, 2025</span></span> /PRNewswire/ — Greenhouse Horticulture Market is Segmented by Type (Plastic, Glass), by Application (Ornamentals, Vegetables, Fruit).</p><div dir="ltr" id="prni_dvprnejpg66aaleft" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="Valuates_Reports_Logo" id="prnejpg66aaleft" src="https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg" title="Valuates_Reports_Logo"></img></div><p>The Global Greenhouse Horticulture Market revenue was <span class="xn-money">USD 21760 Million</span> in 2022 and is forecast to a readjusted size of <span class="xn-money">USD 31370 Million</span> by 2029 with a CAGR of 5.3% during the review period (2023-2029).</p><p><b>Claim Your Free Report: </b><u><a href="https://reports.valuates.com/request/sample/QYRE-Auto-0G16110/Global_and_India_Greenhouse_Horticulture_Market" rel="nofollow" target="_blank">https://reports.valuates.com/request/sample/QYRE-Auto-0G16110/Global_and_India_Greenhouse_Horticulture_Market</a></u></p><p><b>Major Factors Driving the Growth of Greenhouse Horticulture Market:</b></p><p>The global greenhouse horticulture market is experiencing robust growth, propelled by factors such as rising food demand, urbanization, climate change, and technological advancements. Greenhouses offer a viable solution for consistent, high-yield crop production, even in regions with limited arable land or unfavorable weather conditions. The market benefits from increasing consumer demand for fresh, locally grown produce and the growing appeal of sustainable agriculture practices. Both plastic and glass greenhouses are being adopted based on their respective cost, durability, and environmental control advantages. With strong government support, expanding export opportunities, and private sector investments, the greenhouse horticulture industry is poised for continued expansion, playing a pivotal role in addressing global food security and agricultural resilience.</p><p><b>Unlock Insights: View Full Report Now! </b><u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-0G16110/global-and-india-greenhouse-horticulture" rel="nofollow" target="_blank">https://reports.valuates.com/market-reports/QYRE-Auto-0G16110/global-and-india-greenhouse-horticulture</a></u></p><p><b>TRENDS INFLUENCING THE GROWTH OF THE GREENHOUSE HORTICULTURE MARKET:</b></p><p>The cultivation of fruits and vegetables within greenhouse environments has been a significant driver of growth in the horticulture market. Greenhouses offer controlled conditions that mitigate the challenges posed by climate variability, pests, and diseases, ensuring consistent and high-quality produce. This reliability is crucial for meeting the increasing consumer demand for fresh, nutritious, and locally grown fruits and vegetables. Crops such as tomatoes, peppers, cucumbers, and leafy greens thrive in greenhouse settings, where factors like temperature, humidity, and light can be optimized. The ability to produce these crops year-round enhances food security and reduces dependence on seasonal imports. Moreover, greenhouse cultivation supports sustainable practices by enabling efficient water use and reducing the need for chemical inputs. The profitability of high-value crops grown in greenhouses attracts investment and encourages technological innovation in horticulture. As urbanization and health consciousness rise, the demand for greenhouse-grown fruits and vegetables is expected to continue its upward trajectory, further propelling the greenhouse horticulture market.</p><p>Plastic greenhouses have significantly contributed to the expansion of the greenhouse horticulture market by offering cost-effective and adaptable solutions for crop cultivation. These structures utilize plastic films, such as polyethylene, which are more affordable than traditional materials like glass. The flexibility of plastic allows for the construction of various greenhouse designs, catering to different climatic conditions and crop requirements. Moreover, advancements in plastic technology have led to the development of films with enhanced properties, including UV resistance and thermal insulation, improving plant growth conditions. The lightweight nature of plastic greenhouses facilitates easier installation and relocation, making them accessible to small and medium-scale farmers. Additionally, plastic greenhouses enable year-round cultivation, protecting crops from adverse weather and pests, thereby increasing yield and quality. This affordability and versatility have made plastic greenhouses particularly popular in developing regions, where they support food security and sustainable agriculture practices. Consequently, the widespread adoption of plastic greenhouses continues to drive growth in the global greenhouse horticulture market.</p><p>Glass greenhouses play a pivotal role in advancing the greenhouse horticulture market by providing durable and efficient environments for high-value crop production. The transparency of glass allows maximum sunlight penetration, essential for photosynthesis and optimal plant growth. Unlike plastic, glass offers superior longevity and structural integrity, reducing the need for frequent replacements and maintenance. This durability makes glass greenhouses a preferred choice for commercial operations focusing on crops like tomatoes, cucumbers, and ornamental plants. Furthermore, glass structures can be integrated with advanced climate control systems, including automated ventilation, heating, and irrigation, enabling precise regulation of internal conditions. Such control enhances crop yield, quality, and consistency, meeting the demands of both local and export markets. In regions with less favorable outdoor growing conditions, glass greenhouses provide a reliable solution for year-round cultivation. The initial investment in glass greenhouses is offset by their long-term benefits and productivity gains. As the demand for high-quality produce increases globally, the adoption of glass greenhouse technology continues to bolster the growth of the greenhouse horticulture market.</p><p>The escalating global population has intensified the demand for food, necessitating increased agricultural productivity. Greenhouse horticulture addresses this need by enabling controlled environment agriculture, which allows for higher crop yields per unit area compared to traditional farming. By mitigating the effects of adverse weather conditions and pests, greenhouses ensure a stable food supply. This reliability is particularly vital in regions facing food insecurity, where consistent production can alleviate hunger and malnutrition. Additionally, the ability to cultivate crops year-round in greenhouses contributes to a more resilient food system. As the global community seeks solutions to feed a growing population sustainably, greenhouse horticulture emerges as a key strategy, driving its market growth.</p><p>Climate change poses significant risks to agriculture through increased frequency of extreme weather events, shifting growing seasons, and the proliferation of pests and diseases. Greenhouse horticulture mitigates these risks by providing controlled environments that shield crops from external climatic variations. This stability ensures consistent production and reduces crop losses, enhancing food security. Furthermore, greenhouses can be designed to minimize environmental impact through efficient resource use, including water and energy conservation. By offering a sustainable alternative to open-field farming in the face of climate challenges, greenhouse horticulture is gaining traction, fueling market growth.</p><p>Governments worldwide are recognizing the benefits of greenhouse horticulture and are implementing policies and incentives to promote its adoption. These include subsidies for greenhouse construction, tax incentives, and funding for research and development in controlled environment agriculture. Such support lowers the financial barriers for farmers and encourages investment in greenhouse technologies. Additionally, policy frameworks that prioritize food security and sustainable agriculture further bolster the greenhouse horticulture sector. As governmental backing continues to strengthen, it plays a pivotal role in accelerating the growth of the greenhouse horticulture market.</p><p>There is a growing consumer preference for fresh, locally sourced, and pesticide-free produce, driven by health consciousness and environmental awareness. Greenhouse horticulture meets this demand by enabling the production of high-quality fruits and vegetables close to urban centers. This proximity reduces the time between harvest and consumption, preserving nutritional value and taste. Moreover, controlled environments minimize the need for chemical inputs, aligning with consumer desires for cleaner food options. The ability to satisfy these consumer trends positions greenhouse horticulture as a key player in the modern food supply chain, stimulating market growth.</p><p>Greenhouse horticulture facilitates the production of uniform, high-quality crops that meet international standards, opening avenues for export. Countries with advanced greenhouse industries can supply produce to markets with less favorable growing conditions, enhancing global food distribution. This trade contributes to economic growth and diversification for exporting nations. Additionally, the reliability and consistency of greenhouse-grown products make them attractive to international buyers. As global trade in horticultural products expands, the demand for greenhouse cultivation increases, propelling the market forward.</p><p><b>Claim Yours Now! </b><u><a href="https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-0G16110&lic=single-user" rel="nofollow" target="_blank">https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-0G16110&lic=single-user</a></u></p><p><b>GREENHOUSE HORTICULTURE MARKET SHARE:</b></p><p>Global Greenhouse Horticulture key players include Rough Brothers, Richel, Hoogendoorn, Dalsem, Priva, etc. The global top five manufacturers hold a share of about 2.5%.</p><p><span class="xn-location">Europe</span> is the largest market, with a share over 50%, followed by the <span class="xn-location">USA</span> and <span class="xn-location">China</span>, with a share of about 30 percent. <span class="xn-location">Europe</span> currently dominates the market, driven by advanced infrastructure, supportive policies, and a strong emphasis on sustainable agriculture. <span class="xn-location">Asia-Pacific</span> is experiencing rapid growth, particularly in <span class="xn-location">China</span> and <span class="xn-location">India</span>, due to increasing food demand and government initiatives promoting modern farming techniques. <span class="xn-location">North America</span> maintains a significant market share, supported by technological innovation and consumer demand for fresh produce.</p><p>In terms of product, Plastic Greenhouse is the largest segment, with a share about 80%.</p><p>And in terms of application, the largest application is Vegetables, followed by Ornamentals, Fruit, etc.</p><p><b>Key Companies</b>:</p><ul type="disc"><li>Richel</li><li>Hoogendoorn</li><li>Dalsem</li><li>HortiMaX</li><li>Harnois Greenhouses</li><li>Priva</li><li>Ceres greenhouse</li><li>Certhon</li><li>Van Der Hoeven</li><li>Beijing Kingpeng International Hi-Tech</li><li>Oritech</li><li>Rough Brothers</li><li>Trinog-xs (<span class="xn-location">Xiamen</span>) Greenhouse Tech</li><li>Netafim</li><li>Top Greenhouses</li></ul><p><b>Purchase Chapters: </b><u><a href="https://reports.valuates.com/request/chaptercost/QYRE-Auto-0G16110/Global_and_India_Greenhouse_Horticulture_Market" rel="nofollow" target="_blank">https://reports.valuates.com/request/chaptercost/QYRE-Auto-0G16110/Global_and_India_Greenhouse_Horticulture_Market</a></u> </p><p><b>SUBSCRIPTION</b></p><p>We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.</p><p><b>DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS!</b></p><p>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-14J648/global-greenhouse-soil" rel="nofollow" target="_blank">Greenhouse Soil Market</a></u> was valued at <span class="xn-money">USD 4723 Million</span> in the year 2024 and is projected to reach a revised size of <span class="xn-money">USD 5753 Million</span> by 2031, growing at a CAGR of 2.9% during the forecast period.<br /></br>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-2J15743/global-portable-greenhouse" rel="nofollow" target="_blank">Portable Greenhouse Market</a><br /></br></u>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-15H16965/global-vertical-agriculture-greenhouse" rel="nofollow" target="_blank">Vertical Agriculture Greenhouse Market</a><br /></br></u>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-39Y9173/global-greenhouse-nursery-and-flowers" rel="nofollow" target="_blank">Greenhouse, Nursery, And Flowers market</a></u> was valued at <span class="xn-money">USD 551580 Million</span> in 2023 and is anticipated to reach <span class="xn-money">USD 675720 Million</span> by 2030, witnessing a CAGR of 2.5% during the forecast period 2024-2030.<br /></br>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-19Z15181/global-greenhouse-plant-grow-lights" rel="nofollow" target="_blank">Greenhouse Plant Grow Lights Market</a><br /></br></u>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-21B5834/global-smart-agriculture-smart-greenhouse" rel="nofollow" target="_blank">Smart Agriculture Smart Greenhouse Market</a><br /></br></u>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-22X12165/global-greenhouse-drip-irrigation-systems" rel="nofollow" target="_blank">Greenhouse Drip Irrigation Systems Market</a></u> was valued at <span class="xn-money">USD 1449 Million</span> in the year 2024 and is projected to reach a revised size of <span class="xn-money">USD 2578 Million</span> by 2031, growing at a CAGR of 8.7% during the forecast period.<br /></br>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-29U2085/global-greenhouse-equipment" rel="nofollow" target="_blank">Greenhouse Equipment Market</a><br /></br></u>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-4K10213/global-residential-greenhouse" rel="nofollow" target="_blank">Residential Greenhouse Market</a><br /></br></u>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-36L18519/global-greenhouse-environmental-remote-monitoring-system" rel="nofollow" target="_blank">Greenhouse Environmental Remote Monitoring System market</a></u> was valued at <span class="xn-money">USD 1485 Million</span> in 2023 and is anticipated to reach <span class="xn-money">USD 2382 Million</span> by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.<br /></br>– <u><a href="https://reports.valuates.com/market-reports/QYRE-Auto-28U16212/global-greenhouse-coating" rel="nofollow" target="_blank">Greenhouse Coating Market</a></u></p><p><b>DISCOVER OUR VISION: VISIT ABOUT US!</b></p><p>Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.</p><p>Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that’s why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.</p><p>To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources.</p><p><b>GET A FREE QUOTE</b></p><p>Valuates Reports<br /></br><u><a href="mailto:sales@valuates.com" rel="nofollow" target="_blank">sales@valuates.com</a><br /></br></u>For U.S. Toll-Free Call 1-(315)-215-3225<br /></br>WhatsApp: +91-9945648335</p><p>Website:<u><a href="https://reports.valuates.com/" rel="nofollow" target="_blank"> </a><a href="https://reports.valuates.com/" rel="nofollow" target="_blank">https://reports.valuates.com</a><br /></br></u>Blog: <u><a href="https://valuatestrends.blogspot.com/" rel="nofollow" target="_blank">https://valuatestrends.blogspot.com/</a><br /></br></u>Pinterest: <u><a href="https://in.pinterest.com/valuatesreports/" rel="nofollow" target="_blank">https://in.pinterest.com/valuatesreports/</a><br /></br></u>Twitter: <u><a href="https://twitter.com/valuatesreports" rel="nofollow" target="_blank">https://twitter.com/valuatesreports</a><br /></br></u>Facebook: <u><a href="https://www.facebook.com/valuatesreports/" rel="nofollow" target="_blank">https://www.facebook.com/valuatesreports/</a><br /></br></u>YouTube: <u><a href="https://www.youtube.com/@valuatesreports6753" rel="nofollow" target="_blank">https://www.youtube.com/@valuatesreports6753</a></u></p><p><u><a href="https://www.facebook.com/valuateskorean" rel="nofollow" target="_blank">https://www.facebook.com/valuateskorean</a></u> <u><br /></br><a href="https://www.facebook.com/valuatesspanish" rel="nofollow" target="_blank">https://www.facebook.com/valuatesspanish</a></u> <u><br /></br><a href="https://www.facebook.com/valuatesjapanese" rel="nofollow" target="_blank">https://www.facebook.com/valuatesjapanese</a></u> <u><br /></br><a href="https://valuatesreportspanish.blogspot.com/" rel="nofollow" target="_blank">https://valuatesreportspanish.blogspot.com/</a></u> <u><br /></br><a href="https://valuateskorean.blogspot.com/" rel="nofollow" target="_blank">https://valuateskorean.blogspot.com/</a></u> <u><br /></br><a href="https://valuatesgerman.blogspot.com/" rel="nofollow" target="_blank">https://valuatesgerman.blogspot.com/</a></u> <u><br /></br><a href="https://valuatesreportjapanese.blogspot.com/" rel="nofollow" target="_blank">https://valuatesreportjapanese.blogspot.com/</a></u> </p><p>Logo: <a href="https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg</a></p><p> </p><p id="PURL"><img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN77036&sd=2025-04-30" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/global-greenhouse-horticulture-market-surges-innovations-in-plastic-and-glass-greenhouses-driving-growth--valuates-reports-302443040.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/global-greenhouse-horticulture-market-surges-innovations-in-plastic-and-glass-greenhouses-driving-growth–valuates-reports-302443040.html</a></p><p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN77036&Transmission_Id=202504301310PR_NEWS_EURO_ND__EN77036&DateId=20250430" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>]]></content:encoded> </item> <item> <title>Plutus Completes Historic Final Reconciliation of PLU Rewards Pool and Announces Burn Schedule</title> <link>https://thenewsthisweek.co.uk/plutus-completes-historic-final-reconciliation-of-plu-rewards-pool-and-announces-burn-schedule-19156/</link> <dc:creator><![CDATA[PR Newswire]]></dc:creator> <pubDate>Wed, 30 Apr 2025 16:26:00 +0000</pubDate> <category><![CDATA[Brand Post]]></category> <guid isPermaLink="false">https://thenewsthisweek.co.uk/plutus-completes-historic-final-reconciliation-of-plu-rewards-pool-and-announces-burn-schedule-19156/</guid> <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="144" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/04/plutus-completes-historic-final-reconciliation-of-plu-rewards-pool-and-announces-burn-schedule.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>LONDON, April 30, 2025 /PRNewswire/ — Plutus, a pioneer in the tokenisation of real-world assets (RWA) and creator of the first tokenised rewards system, Pluton (PLU) Rewards, laid the foundation for practical blockchain use by tokenising loyalty in 2015, setting a path that many would follow. Today, Plutus remains a leader in fintech, providing on-chain utility […]]]></description> <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="144" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/04/plutus-completes-historic-final-reconciliation-of-plu-rewards-pool-and-announces-burn-schedule.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div><p><span class="legendSpanClass"><span class="xn-location">LONDON</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 30, 2025</span></span> /PRNewswire/ — Plutus, a pioneer in the tokenisation of real-world assets (RWA) and creator of the first tokenised rewards system, Pluton (PLU) Rewards, laid the foundation for practical blockchain use by tokenising loyalty in 2015, setting a path that many would follow. Today, Plutus remains a leader in fintech, providing on-chain utility with real-world savings to customers across the UK and EU.</p><div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"><p> <a href="https://mma.prnewswire.com/media/2677132/Plutus_Logo.html" rel="nofollow" target="_blank"> <img decoding="async" alt="Plutus Logo" src="https://mma.prnewswire.com/media/2677132/Plutus_Logo.jpg" title="Plutus Logo"></img> </a> </p></p></div><p>Nearly a decade after the initial minting of the PLU Rewards Pool in 2016, Plutus has completed its 11th and final reconciliation in collaboration with Haggards & Crowthers, a UK regulated ACAEW Charted Accountant, ensuring complete transparency and verification of all transactions.</p><p>In the final reconciliation period between <span class="xn-chron">July 2024</span> and <span class="xn-chron">April 2025</span>, Plutus cardholders collectively spent approximately <b><span class="xn-money">$190 million</span></b> (equivalent in local currencies), earning <b><span class="xn-money">$13.78 million</span></b> in savings through in-app PLU rewards. This brings the total all-time spend eligible for rewards to <b><span class="xn-money">$811 million</span></b>, out of approximately <b><span class="xn-money">$1 billion</span></b> spent with the Plutus Card, delivering an estimated <b><span class="xn-money">$58 million</span></b> in in-app savings to customers since inception. <br /></br><br /></br>These milestones are built on the groundbreaking 2015 <a href="https://plutus.it/whitepaper2015" rel="nofollow" target="_blank">whitepaper</a> written by Plutus Founder <span class="xn-person">Danial Daychopan</span>. The paper introduced the concept of tokenised loyalty rewards and is also the first recorded document to coin the term “DEX” to describe PlutusDEX, a one-of-a-kind non-custodial crypto-to-fiat exchange, facilitating up to <span class="xn-money">$50 million</span> value in swaps for card top-ups over five years.</p><p>Following the reconciliation of all eligible rewards, <b>2,478,822.91 PLU</b> remains from the original <b>20,000,000 PLU Rewards Pool</b>. This amount will be burned alongside <b>521,177.09 PLU</b> from the Plutus Treasury, bringing the total burn to<b> 3,000,000 PLU</b> starting on <b><span class="xn-chron">20th May 2025</span></b>, and reducing the total supply from <b>20 million to 17 million </b>by<b> <span class="xn-chron">20th July 2025</span></b>.</p><p>Further token burns are scheduled in the coming quarters, aiming to reduce the total supply to <b>13.8 million PLU</b>, with the final burn expected on <b><span class="xn-chron">20th December 2025</span></b>, subject to confirmation. The approach highlights Plutus’ commitment to creating a sustainable, efficient, and transparent reward system.</p><p><i>“The PLU burn marks a shift to a timeless rewards system, ensuring consistent, sustainable savings through our network of partners within the app. This move benefits everyday spenders, paving the way for utility-driven rewards, plus more from your daily card spending.”<br /></br> </i>– Danial Daychopan, Founder & CEO of Plutus.</p><p>The PLU burn marks the end of PLU emissions and is part of Plutus’ shift to a dual-token system. Going forward, only the PLU that customers have already earned will be available for stacking to unlock savings and rewards in the app via connected wallets, with no new PLU being issued. Meanwhile, this will be replaced by a new Dynamic Rewards system, that offers instant, redeemable rewards within the app.</p><p>This strategic shift creates a clear distinction between external stacking and redeemable rewards earned in-app, ensuring greater clarity, and consistent savings for Plutus customers.</p><p><b>For more information:</b></p><ul type="disc"><li><b>Final Reconciliation & Burn: </b><a href="https://www.plutus.it/blog/plu-rewards-pool-final-reconciliation-burn-schedule" rel="nofollow" target="_blank">PLU Rewards Pool | Final Reconciliation & Burn Schedule</a></li><li><b>Dual-Token Upgrade: </b><a href="https://www.plutus.it/blog/new-era-for-stackers-upgrade-to-rare-plu" rel="nofollow" target="_blank">New Era for Stackers: Upgrade to Rare PLU</a></li><li><b>Media Inquiries: </b><a href="mailto:press@plutus.it" rel="nofollow" target="_blank">press@plutus.it</a></li><li><b>Website:</b> <a href="https://www.plutus.it/" rel="nofollow" target="_blank">https://www.plutus.it</a></li></ul><p><b>About Plutus</b></p><p>Plutus is a pioneer in tokenising real-world assets (RWA) and the creator of tokenised rewards, first introduced in 2015 during the early days of blockchain technology. By bridging traditional finance with decentralised systems, Plutus laid the foundation for the tokenisation that followed. Today, Plutus continues to innovate, offering seamless on-chain loyalty rewards, with approximately <span class="xn-money">$1 billion</span> in value spent through the Plutus Card, delivering <span class="xn-money">$58 million</span> worth of real-world savings via the Plutus app. Plutus now leads fintech innovation, empowering customers with unmatched savings and shaping the future of everyday card spending through a sustainable, utility-driven on-chain rewards system.</p><p>Photo – <a href="https://mma.prnewswire.com/media/2677133/Plutus_Rewards.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/2677133/Plutus_Rewards.jpg</a><br /></br>Logo – <a href="https://mma.prnewswire.com/media/2677132/Plutus_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/2677132/Plutus_Logo.jpg</a></p><div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2"><p> <a href="https://mma.prnewswire.com/media/2677133/Plutus_Rewards.html" rel="nofollow" target="_blank"> <img decoding="async" alt="Plutus Rewards" src="https://mma.prnewswire.com/media/2677133/Plutus_Rewards.jpg" title="Plutus Rewards"></img> </a> </p></p></div><p id="PURL"><img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN76940&sd=2025-04-30" title="Cision" width="12"></img> View original content to download multimedia:<a href="https://www.prnewswire.co.uk/news-releases/plutus-completes-historic-final-reconciliation-of-plu-rewards-pool-and-announces-burn-schedule-302442980.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/plutus-completes-historic-final-reconciliation-of-plu-rewards-pool-and-announces-burn-schedule-302442980.html</a></p><p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN76940&Transmission_Id=202504301226PR_NEWS_EURO_ND__EN76940&DateId=20250430" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>]]></content:encoded> </item> <item> <title>ROYAL CANADIAN MINT WINS TWO 2025 MINT DIRECTORS CONFERENCE COIN AWARDS</title> <link>https://thenewsthisweek.co.uk/royal-canadian-mint-wins-two-2025-mint-directors-conference-coin-awards-19158/</link> <dc:creator><![CDATA[PR Newswire]]></dc:creator> <pubDate>Wed, 30 Apr 2025 16:21:00 +0000</pubDate> <category><![CDATA[Brand Post]]></category> <guid isPermaLink="false">https://thenewsthisweek.co.uk/royal-canadian-mint-wins-two-2025-mint-directors-conference-coin-awards-19158/</guid> <description><![CDATA[The Mint earns global industry recognition for a double-sided Extraordinarily High Relief pure silver coin celebrating the Year of the Dragon and its collaboration with McGill University on a more environementally responsible gold refining process OTTAWA, ON, April 30, 2025 /PRNewswire/ — The Royal Canadian Mint is delighted to have twice earned global recognition for its coin […]]]></description> <content:encoded><![CDATA[<p class="prntac"><i>The Mint earns global industry recognition for a double-sided </i><i>Extraordinarily High Relief</i> <i>pure silver coin celebrating the Year of the Dragon and its collaboration with <span class="xn-org">McGill University</span> on a more environementally responsible gold refining </i><i>process</i></p><p><span class="legendSpanClass"><span class="xn-location">OTTAWA, ON</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 30, 2025</span></span> /PRNewswire/ — The Royal Canadian Mint is delighted to have twice earned global recognition for its coin manufacturing execellence and innovation by winning the <i>Best Commemorative Silver Coin </i>and the <i>Best Collaboration</i> coin awards of the 2025 Mint Directors Conference (MDC). The Mint was first recognized for its 2024 <span class="xn-money">$50</span> Pure Silver Coin – Year of the Dragon, a new technical achievement that enhances the relief of a stunning Wood Dragon design to an impressive height of 4.7 mm on the reverse and created a rear view of the dragon in an equally impressive obverse relief. As well, our partnership with the Department of Chemistry at <span class="xn-location">Montreal’s</span> McGill University, to develop a more environmentally responsible gold refining process, was recognized as the global minting industry’s best collaboration.</p><p>The 2025 MDC is host to the prestigious Coin Awards, recognising industry achievements in the design, production, packaging, and distribution of commemorative and circulating coins worldwide.</p><p>“The Royal Canadian Mint is passionate about innovating to keep demonstrating the excellence and artistry of our world-famous coin products, as well as the sustainability of our processes,” said <span class="xn-person">Marie Lemay</span>, President and CEO of the Royal Canadian Mint. “To be recognized in two award categories by the Mint Directors Conference judges is a tremendous peer endorsement of our commitment to finding new ways to delight our customers while finding more caring and sustainable ways to continue leading the global minting community.”</p><p>Designed by Canadian artist <span class="xn-person">Simon Ng</span>, our award-winning pure silver coin celebrates the Year of the Wood Dragon through an elaborate EHR engraving of a dragon, the fifth sign in the Chinese Zodiac. Framed by a laser-engraved pattern that represents the wood element, the dragon is shown moving among the clouds of a night sky illuminated by the moon, its tail coiled to form the shape of lucky number 8. A rear view of that same scene is rendered in EHR on the obverse. Above the obverse engraving appears the effigy of <span class="xn-person">Queen Elizabeth II</span> by <span class="xn-person">Susanna Blunt</span>, accompanied by a special device of four pearls symbolizing her four different effigies to have graced Canadian coins, as well as the double date of her reign. </p><p>The goal of the Mint’s work with <span class="xn-org">McGill University</span> is to transform gold refining by replacing the longstanding Miller Chlorination process, which relies on the injection of chlorine gas separate impurities from molten gold. Our collaboration has, at a lab scale, resulted in a process that eliminates chlorine gas almost entirely by introducing an acoustic mechanochemical process to catalyze a chemical reaction with a mild reagent. The process, which yields pure gold in soluble form is non-toxic and less energy-intensive, and is safer for people and the environment.</p><p>This innovation builds on previous work done by the Mint in 2019 to reduce chlorine use in its gold refining operations. At that time, the Mint introduced acid-less separation (ALS) technology, that reduced the use of chlorine gas by more than 50% in the <span class="xn-location">Ottawa</span> refinery.</p><p><b>Images and video of the 2024 Pure Silver Coin – Year of the Dragon</b> <b>can</b><b> be found </b><a href="https://c212.net/c/link/?t=0&l=en&o=4417144-1&h=2018750639&u=https%3A%2F%2Fwww.dropbox.com%2Fscl%2Ffo%2Fc79smf620uw1ukagzroi8%2Fh%3Frlkey%3D6xis0bvou5rszh7a7vw02002a%26dl%3D0&a=here" rel="nofollow" target="_blank"><b>here</b></a><b>. </b></p><p><b>About the Royal Canadian Mint</b></p><p>The Royal Canadian Mint is the Crown corporation responsible for the minting and distribution of <span class="xn-location">Canada’s</span> circulation coins. The Mint is one of the largest and most versatile mints in the world, producing award-winning collector coins, market-leading bullion products, as well as <span class="xn-location">Canada’s</span> prestigious military and civilian honours. As an established <span class="xn-location">London</span> and COMEX Good Delivery refiner, the Mint also offers a full spectrum of best-in-class gold and silver refining services. As an organization that strives to take better care of the environment, to cultivate safe and inclusive workplaces and to make a positive impact on the communities where it operates, the Mint integrates environmental, social and governance practices in every aspect of its operations. </p><p>For more information on the Mint, its products and services, visit <a href="https://c212.net/c/link/?t=0&l=en&o=4417144-1&h=1535320184&u=http%3A%2F%2Fwww.mint.ca%2F&a=www.mint.ca" rel="nofollow" target="_blank">www.mint.ca</a>. Follow the Mint on <a href="https://c212.net/c/link/?t=0&l=en&o=4417144-1&h=908196072&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Froyal-canadian-mint%2F&a=LinkedIn" rel="nofollow" target="_blank">LinkedIn</a>, <a href="https://c212.net/c/link/?t=0&l=en&o=4417144-1&h=3069342357&u=https%3A%2F%2Fwww.facebook.com%2FCanadianMint%2F&a=Facebook" rel="nofollow" target="_blank">Facebook</a> and <a href="https://c212.net/c/link/?t=0&l=en&o=4417144-1&h=1453942484&u=https%3A%2F%2Fwww.instagram.com%2Fcanadianmint%2F&a=Instagram" rel="nofollow" target="_blank">Instagram</a>.</p><p><span>For more information, please contact: <span class="xn-person">Alex Reeves</span>, Senior Manager, Public Affairs, (613) 884-6370, <a href="mailto:reeves@mint.ca" rel="nofollow">reeves@mint.ca</a></span></p><p id="PURL"><img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN76961&sd=2025-04-30" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/royal-canadian-mint-wins-two-2025-mint-directors-conference-coin-awards-302442975.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/royal-canadian-mint-wins-two-2025-mint-directors-conference-coin-awards-302442975.html</a></p><p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN76961&Transmission_Id=202504301221PR_NEWS_EURO_ND__EN76961&DateId=20250430" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>]]></content:encoded> </item> <item> <title>Eyewear Market to be worth $335.90 Billion by 2030 at CAGR 8.6% – Grand View Research, Inc.</title> <link>https://thenewsthisweek.co.uk/eyewear-market-to-be-worth-335-90-billion-by-2030-at-cagr-8-6-grand-view-research-inc-19159/</link> <dc:creator><![CDATA[PR Newswire]]></dc:creator> <pubDate>Wed, 30 Apr 2025 15:55:00 +0000</pubDate> <category><![CDATA[Brand Post]]></category> <guid isPermaLink="false">https://thenewsthisweek.co.uk/eyewear-market-to-be-worth-335-90-billion-by-2030-at-cagr-8-6-grand-view-research-inc-19159/</guid> <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="44" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/04/eyewear-market-to-be-worth-335-90-billion-by-2030-at-cagr-8-6-grand-view-research-inc.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>SAN FRANCISCO, April 30, 2025 /PRNewswire/ — The global eyewear market size is expected to reach USD 335.90 billion by 2030, registering a CAGR of 8.6% CAGR from 2025 to 2030, according to a new report by Grand View Research, Inc. As eyewear has evolved from being purely functional to becoming a fashion accessory, consumers are […]]]></description> <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="44" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/04/eyewear-market-to-be-worth-335-90-billion-by-2030-at-cagr-8-6-grand-view-research-inc.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div><p><span class="legendSpanClass"><span class="xn-location">SAN FRANCISCO</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 30, 2025</span></span> /PRNewswire/ — The global <a href="https://www.grandviewresearch.com/industry-analysis/eyewear-industry" rel="nofollow" target="_blank">eyewear market</a> size is expected to reach <span class="xn-money">USD 335.90 billion</span> by 2030, registering a CAGR of 8.6% CAGR from 2025 to 2030, according to a new report by Grand View Research, Inc. As eyewear has evolved from being purely functional to becoming a fashion accessory, consumers are increasingly seeking out stylish and trendy frames that complement their personal style. This trend has led to a proliferation of eyewear options, including designer brands, vintage styles, and customizable frames. The availability of a wide range of eyewear choices has made it easier for consumers to find frames that suit their aesthetic preferences, enhancing the outlook for the market.</p><div dir="ltr" id="prni_dvprnejpgb1f6left" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="Grand View Research Logo" id="prnejpgb1f6left" src="https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg" style="width: 400px; height: 121px;" title="Grand View Research Logo"></img></div><p>The market growth is further accelerated by the growing awareness regarding eye health among people, urging them to seek professional advice and invest in quality eyewear. Moreover, sunglasses are also in high demand not only as a fashion accessory but also as protection for the eyes from harmful UV rays. As people recognize the importance of eye health, they are more likely to embrace eyewear as a necessary and even fashionable accessory.</p><p>The growing awareness of eye health initiatives by government organizations is playing a significant role in driving the growth of the market. Governments worldwide are implementing programs and campaigns to educate the public about the importance of regular eye exams, early detection of eye conditions, and the use of appropriate eyewear. These initiatives are raising awareness about the potential consequences of neglecting eye health, encouraging individuals to seek professional care, and ultimately stimulating demand for eyewear products.</p><p>Technological advancements are also playing a crucial role in driving the growth of the market. Increased screen time is a rising concern about the impact of blue light on eye health. Eyewear designed specifically for blue light protection presents a market niche, catering to individuals seeking solutions for digital eye strain. On the other hand, innovative applications, including the integration of augmented reality (AR) and virtual reality (VR) into eyewear, provide opportunities for innovative, multifunctional products.</p><p>Several market players are focusing on developing innovative offerings that can cater to evolving consumer demands. For instance, in <span class="xn-chron">April 2024</span>, Meta and EssilorLuxottica launched the second-generation smart glasses, expanding the Ray-Ban Meta smart glasses range with new designs that can fit more face shapes. The latest offering features Meta AI, an intelligent assistant that follows voice commands. Amid such technological developments, the eyewear market is poised for considerable growth over the coming years.</p><p><b>Read full market research report on </b><b>Eyewear Market</b> <b>with TOC</b> <b>“</b><a href="https://www.grandviewresearch.com/industry-analysis/eyewear-industry" rel="nofollow" target="_blank"><b><i>Eyewear Market Size, Share & Trends Analysis Report By Product (Contact Lenses, Prescription (RX) Glasses, Sunglasses), By Distribution Channel (E-Commerce, Brick & Mortar), By End Use (Female, Kids), By Price Range, By Region, And Segment Forecasts, 2025 – 2030</i></b></a><b>“</b></p><p><b><u>Eyewear Market Report Highlights</u></b></p><ul type="disc"><li>Based on product, the prescription (RX) glasses segment accounted for the largest revenue in 2024 owing to increasing demand for corrective eyewear driven by the rising prevalence of eye conditions such as myopia, hyperopia, astigmatism, and presbyopia. Moreover, the availability of a wide range of prescription eyewear options further underlines the dominance of the segment within the market.<br /></br><br /></br></li><li>Based on distribution channel, the e-commerce segment is expected to record the fastest CAGR from 2025 to 2030 owing to increasing consumer preference for online shopping sites to buy eyewear products as they offer greater convenience and accessibility. Online retailers offer a wider range of products, including designer brands and niche offerings, often at competitive prices, which is contributing to the segmental growth further.<br /></br><br /></br></li><li>Based on end use, the kids segment is expected to record the fastest CAGR from 2025 to 2030, with increasing awareness among parents about the importance of protecting children’s eyesight from an early age, stimulating the demand for eyewear in this segment. In addition, the availability of stylish and durable kids’ eyewear options is also favoring segmental growth as they appeal to both children and parents.<br /></br><br /></br></li><li>In July 2024, EssilorLuxottica announced its agreement to acquire the entire share capital of Optical Investment Group, a leading Romanian optical retailer, from Innova/6, a private equity fund of Innova Capital Group, and minority shareholders. This acquisition is seen as a significant step in enhancing <span class="xn-location">Romania’s</span> optical market, promoting quality eyewear and eye care solutions</li></ul><p><b>Request a free sample copy or view report summary</b>: <a href="https://www.grandviewresearch.com/industry-analysis/eyewear-industry/request/rs1" rel="nofollow" target="_blank">Eyewear Market</a></p><p><b>Eyewear Market Segmentation</b></p><p>Grand View Research has segmented the global eyewear market report based on product, distribution channel, end use, and region:</p><p><b>Eyewear Market – Product Outlook (Volume, Million Units; Revenue, USD Million, 2018 – 2030)</b></p><ul type="disc"><li>Contact Lenses<ul type="disc"><li>Premium Contact Lenses</li><li>Mass Contact Lenses</li></ul></li><li>Prescription (RX) Glasses<ul type="disc"><li>Prescription Glasses, by Frame<ul type="disc"><li>Frame Type<ul type="disc"><li>Full Frame</li><li>Half Frame</li><li>Rimless</li></ul></li><li>Frame Style<ul type="disc"><li>Round</li><li>Square</li><li>Rectangle</li><li>Oval</li><li>Others</li></ul></li><li>Frame Material<ul type="disc"><li>Metal</li><li>Nylon</li><li>Others</li></ul></li></ul></li><li>Prescription Glasses, by Lens<ul type="disc"><li>Single Vision Lenses</li><li>Multi-vision Lenses</li><li>Progressive Lenses</li><li>Others</li></ul></li></ul></li><li>Sunglasses<ul type="disc"><li>Sunglasses, by Frame<ul type="disc"><li>Frame Type<ul type="disc"><li>Full Frame</li><li>Half Frame</li><li>Rimless</li></ul></li><li>Frame Style<ul type="disc"><li>Round</li><li>Square</li><li>Rectangle</li><li>Oval</li><li>Others</li></ul></li><li>Frame Material<ul type="disc"><li>Metal</li><li>Nylon</li><li>Others</li></ul></li></ul></li><li>Sunglasses, by Lens<ul type="disc"><li>Lens Type<ul type="disc"><li>Polarized Sunglasses</li><li>Non-Polarized Sunglasses</li></ul></li><li>Lens Material<ul type="disc"><li>CR-39</li><li>Polycarbonate</li><li>Polyurethane</li><li>Others</li></ul></li></ul></li></ul></li></ul><p><b>Eyewear Market – Distribution Channel Outlook (Volume, Million Units; Revenue, USD Million, 2018 – 2030)</b></p><ul type="disc"><li>E-Commerce</li><li>Brick & Mortar</li></ul><p><b>Eyewear Market – End Use Outlook (Volume, Million Units; Revenue, USD Million, 2018 – 2030)</b></p><ul type="disc"><li>Male</li><li>Female</li><li>Unisex</li><li>Kids</li></ul><p><b>Eyewear Price Range Outlook (Volume, Million Units; Revenue, USD Million, 2018 – 2030)</b></p><ul type="disc"><li><span class="xn-money">$0</span>–<span class="xn-money">$150</span></li><li><span class="xn-money">$150</span>–<span class="xn-money">$250</span></li><li><span class="xn-money">$250</span>–<span class="xn-money">$300</span></li><li><span class="xn-money">$300</span>–<span class="xn-money">$500</span></li><li>$500+</li></ul><p><b>Eyewear Market – Regional Outlook (Volume, Million Units; Revenue, USD Million, 2018 – 2030)</b></p><ul type="disc"><li><span class="xn-location">North America</span><ul type="disc"><li>U.S.</li><li><span class="xn-location">Canada</span></li><li><span class="xn-location">Mexico</span></li></ul></li><li><span class="xn-location">Europe</span><ul type="disc"><li><span class="xn-location">Germany</span></li><li>UK</li><li><span class="xn-location">France</span></li><li><span class="xn-location">Italy</span></li><li><span class="xn-location">Spain</span></li><li><span class="xn-location">Austria</span></li><li><span class="xn-location">Belgium</span></li><li><span class="xn-location">Czech Republic</span></li><li><span class="xn-location">Denmark</span></li><li><span class="xn-location">Finland</span></li><li><span class="xn-location">France</span></li><li><span class="xn-location">Iceland</span></li><li><span class="xn-location">Ireland</span></li><li><span class="xn-location">Italy</span></li><li><span class="xn-location">Netherlands</span></li><li><span class="xn-location">Norway</span></li><li><span class="xn-location">Poland</span></li><li><span class="xn-location">Spain</span></li><li><span class="xn-location">Sweden</span></li><li><span class="xn-location">Switzerland</span></li></ul></li><li><span class="xn-location">Asia Pacific</span><ul type="disc"><li><span class="xn-location">China</span></li><li><span class="xn-location">India</span></li><li><span class="xn-location">Australia</span></li><li><span class="xn-location">Hong Kong</span></li><li><span class="xn-location">Indonesia</span></li><li><span class="xn-location">Japan</span></li><li><span class="xn-location">Malaysia</span></li><li><span class="xn-location">New Zealand</span></li><li><span class="xn-location">Philippines</span></li><li><span class="xn-location">Singapore</span></li><li><span class="xn-location">South Korea</span></li><li><span class="xn-location">Taiwan</span></li><li><span class="xn-location">Thailand</span></li><li><span class="xn-location">Vietnam</span></li></ul></li><li><span class="xn-location">Latin America</span><ul type="disc"><li><span class="xn-location">Brazil</span></li><li><span class="xn-location">Argentina</span></li><li><span class="xn-location">Chile</span></li></ul></li><li><span class="xn-location">Middle East</span> and <span class="xn-location">Africa</span> (MEA)<ul type="disc"><li><span class="xn-location">Israel</span></li><li><span class="xn-location">Nigeria</span></li><li><span class="xn-location">Saudi Arabia</span></li><li><span class="xn-location">South Africa</span></li><li><span class="xn-location">Turkey</span></li><li>UAE</li></ul></li></ul><p><b>List of Key Players of Eyewear Market</b></p><ul type="disc"><li>Bausch + Lomb Corporation</li><li>Zeiss Group</li><li>CHARMANT INC.</li><li>CHEMIGLAS CORPORATION</li><li>CooperVision Limited</li><li>De Rigo Vision S.p.A.</li><li>ESSILORLUXOTTICA</li><li>Fielmann AG</li><li>HOYA Corporation</li><li>JINS Inc.</li><li>Johnson & Johnson Vision Care Inc.</li><li>Marchon Eyewear Inc.</li><li>Marcolin S.p.A.</li><li>Prada S.p.A</li><li>Rodenstock GmbH</li><li>Safilo Group S.p.A</li><li>Seiko Optical Products Co. Ltd.</li><li>Shamir Optical Industry Ltd.</li><li>Silhouette International Schmied AG</li><li><span class="xn-person">Warby Parker</span></li><li>Zenni Optical Inc.</li></ul><p><b>Check out more related studies published by Grand View Research:</b></p><ul type="disc"><li><b><a href="https://www.grandviewresearch.com/industry-analysis/sports-eyewear-market" rel="nofollow" target="_blank">Sports Eyewear Market</a></b><b> – </b>The global sports eyewear market size is expected to reach <span class="xn-money">USD 24.61 billion</span> by 2030, registering a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising demand for lightweight goggles or sunglasses with dynamic designs is expected to be a key growth-driving factor for the market.<br /></br><br /></br></li><li><b><a href="https://www.grandviewresearch.com/industry-analysis/safety-eyewear-market" rel="nofollow" target="_blank">Safety Eyewear Market</a></b><b> – </b>The global safety eyewear market size is expected to reach <span class="xn-money">USD 5.31 billion</span> by 2030, growing at a CAGR of 3.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is poised for influential growth due to increasing awareness of workplace safety, stringent government regulations, and rising incidences of eye injuries in the industrial and construction sectors.<br /></br><br /></br></li><li><b><a href="https://www.grandviewresearch.com/industry-analysis/us-eyewear-market-report" rel="nofollow" target="_blank">U.S. Eyewear Market</a></b><b> – </b>The U.S. eyewear market size is expected to reach <span class="xn-money">USD 62.78 billion</span> by 2030 and is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030. Due to the changing lifestyle patterns and increasing adoption of luxurious accessories, especially among millennials, the market is expected to grow. Growing visual inaccuracies, coupled with increased awareness regarding vision correction, are expected to drive market growth. Consistent renewal of spectacle lenses due to the constant change in prescriptions is expected to influence the demand positively over the forecast period.</li></ul><p><b>About Grand View Research</b></p><p>Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in <span class="xn-location">California</span> and headquartered in <span class="xn-location">San Francisco</span>, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.</p><p>Explore <b><a href="https://www.grandviewresearch.com/horizon/" rel="nofollow" target="_blank">Horizon Databook</a></b> – The world’s most expansive market intelligence platform developed by Grand View Research. Gain insights from 30K+ Global & Regional Reports, 120K+ Country Reports, 1.2M+ Market Statistics, 200K+ Company Profiles, and 5 business solutions encompassing ESG and Sustainability Consulting, Procurement Intelligence, Pricing Index and Analysis, and Consumer Analytics.</p><p><b>Contact:</b></p><p><span class="xn-person">Sherry James</span><br /></br>Corporate Sales Specialist, <span class="xn-location">USA</span><br /></br>Grand View Research, Inc.<br /></br>Phone: 1-415-349-0058<br /></br>Toll Free: 1-888-202-9519<br /></br>Email: <a href="mailto:sales@grandviewresearch.com" rel="nofollow" target="_blank">sales@grandviewresearch.com</a><br /></br>Web: <a href="https://www.grandviewresearch.com/" rel="nofollow" target="_blank">https://www.grandviewresearch.com</a><br /></br>Follow Us: <a href="https://www.linkedin.com/company/grand-view-research/" rel="nofollow" target="_blank">LinkedIn</a> | <a href="https://twitter.com/GrandViewInc" rel="nofollow" target="_blank">Twitter</a></p><p>Logo – <a href="https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg</a></p><p id="PURL"><img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN76788&sd=2025-04-30" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/eyewear-market-to-be-worth-335-90-billion-by-2030-at-cagr-8-6---grand-view-research-inc-302442780.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/eyewear-market-to-be-worth-335-90-billion-by-2030-at-cagr-8-6—grand-view-research-inc-302442780.html</a></p><p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN76788&Transmission_Id=202504301155PR_NEWS_EURO_ND__EN76788&DateId=20250430" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.</p>]]></content:encoded> </item> </channel></rss> If you would like to create a banner that links to this page (i.e. this validation result), do the following:
Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):
If you would like to create a text link instead, here is the URL you can use:
http://www.feedvalidator.org/check.cgi?url=https%3A//thenewsthisweek.co.uk/feed/
